WEBVTT

NOTE duration:"00:54:41"

NOTE recognizability:0.851

NOTE language:en-us

NOTE Confidence: 0.61968868

00:00:00.000 --> 00:00:02.538 32 Cancer Center grain grand rounds.

NOTE Confidence: 0.61968868

00:00:02.540 --> 00:00:04.112 I'm making a guest appearance today

NOTE Confidence: 0.61968868

00:00:04.112 --> 00:00:06.156 and I can't say that it's wonderful

NOTE Confidence: 0.61968868

00:00:06.156 --> 00:00:09.032 to be a guest in introducing a very

NOTE Confidence: 0.61968868

00:00:09.032 --> 00:00:11.456 special speaker who is Doctor Kathy

NOTE Confidence: 0.61968868

00:00:11.456 --> 00:00:14.275 Yang and many of us know Doctor Ang

NOTE Confidence: 0.61968868

00:00:14.275 --> 00:00:17.628 who is very well known in the field of

NOTE Confidence: 0.61968868

00:00:17.628 --> 00:00:20.268 Colt GI Malignancies and Doctor Lang.

NOTE Confidence: 0.61968868

00:00:20.270 --> 00:00:23.077 Is the David Johnson chair and surgical

NOTE Confidence: 0.61968868

00:00:23.077 --> 00:00:25.096 and medical oncology, and she's Co.

NOTE Confidence: 0.61968868

00:00:25.096 --> 00:00:28.140 Leader of the GI Cancers research program.

NOTE Confidence: 0.61968868

00:00:28.140 --> 00:00:30.338 At Vanderbilt, she's also, I think Co.

NOTE Confidence: 0.61968868

00:00:30.340 --> 00:00:32.908 Director of the OR Director of the Young

NOTE Confidence: 0.61968868

00:00:32.908 --> 00:00:35.084 Adults Cancer Initiative and started at

NOTE Confidence: 0.61968868

00:00:35.084 --> 00:00:37.292 Vanderbilt about a couple years ago,

NOTE Confidence: 0.61968868

00:00:37.300 --> 00:00:40.970 so really has done phenomenally.

NOTE Confidence: 0.61968868

00:00:40.970 --> 00:00:42.980 Kathy received her MD from Hahnemann

NOTE Confidence: 0.61968868

00:00:42.980 --> 00:00:45.037 and then her residency in internal

NOTE Confidence: 0.61968868

00:00:45.037 --> 00:00:47.340 medicine at Russia and then did her

NOTE Confidence: 0.61968868

00:00:47.340 --> 00:00:49.180 fellowship in hematology oncology at

NOTE Confidence: 0.61968868

00:00:49.180 --> 00:00:51.336 the University of Chicago and then

NOTE Confidence: 0.61968868

00:00:51.336 --> 00:00:53.807 spent majority of her life at MD.

NOTE Confidence: 0.61968868

00:00:53.810 --> 00:00:56.750 Anderson focused on what is close to,

NOTE Confidence: 0.61968868

00:00:56.750 --> 00:00:58.465 I think several of our hearts in

NOTE Confidence: 0.61968868

00:00:58.465 --> 00:01:00.269 in focused on colorectal cancers,

NOTE Confidence: 0.61968868

00:01:00.270 --> 00:01:03.336 GI cancers and translational research and

NOTE Confidence: 0.61968868

00:01:03.336 --> 00:01:07.348 what impact can we do in in those fields.

NOTE Confidence: 0.61968868

00:01:07.350 --> 00:01:09.420 She also played important roles in

NOTE Confidence: 0.61968868

00:01:09.420 --> 00:01:11.160 faculty governance. I was excited to see.

NOTE Confidence: 0.61968868

00:01:11.160 --> 00:01:13.785 Kathy ticker roll in as in the

NOTE Confidence: 0.61968868

00:01:13.785 --> 00:01:14.535 faculty Senate,

NOTE Confidence: 0.61968868

00:01:14.540 --> 00:01:16.490 which often is an important piece

NOTE Confidence: 0.61968868

00:01:16.490 --> 00:01:19.072 and then move to Vanderbilt in 2019.

NOTE Confidence: 0.61968868

00:01:19.072 --> 00:01:21.304 Her interest has been in clinical

NOTE Confidence: 0.61968868

00:01:21.304 --> 00:01:24.059 trials and how can we define novel

NOTE Confidence: 0.61968868

00:01:24.059 --> 00:01:26.411 drugs for treatment of these cancers.

NOTE Confidence: 0.61968868

00:01:26.420 --> 00:01:27.544 And as I mentioned,

NOTE Confidence: 0.61968868

00:01:27.544 --> 00:01:30.047 is also beyond focus on the young adult

NOTE Confidence: 0.61968868

00:01:30.047 --> 00:01:31.932 colorectal cancer patients has also

NOTE Confidence: 0.61968868

00:01:31.932 --> 00:01:34.499 focused on role of immunotherapy in HP.

NOTE Confidence: 0.61968868

00:01:34.500 --> 00:01:37.340 Associated Cancers has published many,

NOTE Confidence: 0.61968868

00:01:37.340 --> 00:01:38.995 many papers on these fields

NOTE Confidence: 0.61968868

00:01:38.995 --> 00:01:40.650 and has led many trials.

NOTE Confidence: 0.61968868

00:01:40.650 --> 00:01:41.970 I'm not going to enumerate.

NOTE Confidence: 0.61968868

00:01:41.970 --> 00:01:45.253 All of the her leadership roles in

NOTE Confidence: 0.61968868

00:01:45.253 --> 00:01:47.450 the various national societies in

NOTE Confidence: 0.61968868

00:01:47.450 --> 00:01:50.598 ASCO ASCO GI E Cog and see I most

NOTE Confidence: 0.61968868

00:01:50.598 --> 00:01:53.034 recently that rang was chosen as the

NOTE Confidence: 0.61968868

00:01:53.034 --> 00:01:55.606 Vice chair of the swag GI Committee

NOTE Confidence: 0.61968868

00:01:55.606 --> 00:01:58.196 and NCI GI Steering Committee and also

NOTE Confidence: 0.61968868

00:01:58.196 --> 00:02:00.136 has focused on workforce shortages.

NOTE Confidence: 0.61968868

00:02:00.140 --> 00:02:00.712 So overall,

NOTE Confidence: 0.61968868

00:02:00.712 --> 00:02:02.714 what I would describe as not only

NOTE Confidence: 0.61968868

00:02:02.714 --> 00:02:04.230 a talented clinician,

NOTE Confidence: 0.61968868

00:02:04.230 --> 00:02:06.108 but also thinking about our field

NOTE Confidence: 0.61968868

00:02:06.108 --> 00:02:08.099 and oncology and the broader things

NOTE Confidence: 0.61968868

00:02:08.099 --> 00:02:09.110 that guide us.

NOTE Confidence: 0.61968868

00:02:09.110 --> 00:02:11.768 So really looking forward to her

NOTE Confidence: 0.61968868

00:02:11.768 --> 00:02:13.400 presentation today. Welcome, Kathy.

NOTE Confidence: 0.61968868

00:02:13.400 --> 00:02:15.620 You're only sorry this is virtual.

00:02:16.160 --> 00:02:20.237 Well, thank you so much and let me go

00:02:20.237 --> 00:02:26.300 ahead and share my screen. And. Sorry.

00:02:34.630 --> 00:02:38.067 OK, did did it come across OK?

00:02:38.070 --> 00:02:40.776 Perfect so today is March 1st,

00:02:40.780 --> 00:02:42.910 so it's colorectal Cancer Awareness Month,

00:02:42.910 --> 00:02:46.844 so I am delighted to participate in

00:02:46.844 --> 00:02:48.503 this session with all of you today.

00:02:48.510 --> 00:02:51.866 With so many familiar faces and

00:02:51.866 --> 00:02:55.128 thank you so much for inviting me.

00:02:55.130 --> 00:02:59.195 So we'll just be touching up on kind of the

00:02:59.195 --> 00:03:01.070 general field regarding colorectal cancer,

00:03:01.070 --> 00:03:03.896 since it seems appropriate for March

00:03:03.896 --> 00:03:05.780 colorectal Cancer Awareness Month.

00:03:05.780 --> 00:03:09.188 And these are the topics we'll be discussing.

00:03:12.050 --> 00:03:15.280 And these are my disclosures.

00:03:15.280 --> 00:03:17.195 So friendly reminder for those

NOTE Confidence: 0.94186048

00:03:17.195 --> 00:03:19.110 that are don't treat colorectal

NOTE Confidence: 0.94186048

00:03:19.180 --> 00:03:20.790 cancer in a regular basis.

NOTE Confidence: 0.94186048

00:03:20.790 --> 00:03:24.118 It is expected in 2022 that 151,000

NOTE Confidence: 0.94186048

00:03:24.118 --> 00:03:25.808 individuals will be diagnosed with

NOTE Confidence: 0.94186048

00:03:25.808 --> 00:03:27.819 this disease and about 45 thousand

NOTE Confidence: 0.94186048

00:03:27.819 --> 00:03:29.613 of those will be rectal carcinoma.

NOTE Confidence: 0.94186048

00:03:29.620 --> 00:03:31.198 It still remains the second leading

NOTE Confidence: 0.94186048

00:03:31.198 --> 00:03:33.028 cause of cancer death for men and

NOTE Confidence: 0.94186048

00:03:33.028 --> 00:03:34.474 women combined and the meeting age.

NOTE Confidence: 0.94186048

00:03:34.480 --> 00:03:36.027 As many of you are aware is

NOTE Confidence: 0.94186048

00:03:36.027 --> 00:03:37.220 usually in the late 60s,

NOTE Confidence: 0.94186048

00:03:37.220 --> 00:03:39.138 but I'm going to be touching upon

NOTE Confidence: 0.94186048

00:03:39.138 --> 00:03:41.356 that because of my own interest in

NOTE Confidence: 0.94186048

00:03:41.356 --> 00:03:43.033 early onset colorectal cancer and

NOTE Confidence: 0.94186048

00:03:43.033 --> 00:03:45.697 for as long as I've been in practice.

NOTE Confidence: 0.94186048

00:03:45.700 --> 00:03:46.062 Unfortunately,

NOTE Confidence: 0.94186048

00:03:46.062 --> 00:03:48.596 the five year survival for our stage

NOTE Confidence: 0.94186048

00:03:48.596 --> 00:03:50.545 four patient population has basically

NOTE Confidence: 0.94186048

00:03:50.545 --> 00:03:53.279 only changed from about 13 to 14%,

NOTE Confidence: 0.94186048

00:03:53.279 --> 00:03:56.096 and it looks closer now to 15%.

NOTE Confidence: 0.94186048

00:03:56.096 --> 00:03:57.920 Based upon these numbers.

NOTE Confidence: 0.882954597

00:04:00.550 --> 00:04:02.410 Friendly reminder as well for

NOTE Confidence: 0.882954597

00:04:02.410 --> 00:04:04.270 the majority of our patients.

NOTE Confidence: 0.882954597

00:04:04.270 --> 00:04:06.922 Unfortunately they do not have an

NOTE Confidence: 0.882954597

00:04:06.922 --> 00:04:09.190 inherited form of colorectal cancer

NOTE Confidence: 0.882954597

00:04:09.190 --> 00:04:11.290 such as Lynch syndrome or FAP.

NOTE Confidence: 0.882954597

00:04:11.290 --> 00:04:13.378 In the majority of cases are

NOTE Confidence: 0.882954597

00:04:13.378 --> 00:04:15.852 going to be sporadic and that's

NOTE Confidence: 0.882954597

00:04:15.852 --> 00:04:18.557 why this is very difficult.

NOTE Confidence: 0.882954597

00:04:18.560 --> 00:04:21.598 Cancer for us to tackle because I

NOTE Confidence: 0.882954597

00:04:21.598 --> 00:04:24.190 believe it's largely multifactorial.

NOTE Confidence: 0.882954597

00:04:24.190 --> 00:04:25.780 I'm not going to be touching

NOTE Confidence: 0.882954597

00:04:25.780 --> 00:04:27.329 upon the very basic information

NOTE Confidence: 0.882954597

00:04:27.329 --> 00:04:28.607 regarding chemotherapy because

NOTE Confidence: 0.882954597

00:04:28.607 --> 00:04:30.737 most of the literature nowadays

NOTE Confidence: 0.882954597

00:04:30.737 --> 00:04:32.550 is about molecular subsets,

NOTE Confidence: 0.882954597

00:04:32.550 --> 00:04:34.652 and I'll touch upon the more recent

NOTE Confidence: 0.882954597

00:04:34.652 --> 00:04:36.704 data on some of those subsets.

NOTE Confidence: 0.882954597

00:04:36.710 --> 00:04:39.518 But for us for any stage

NOTE Confidence: 0.882954597

00:04:39.518 --> 00:04:40.922 4 surgically unresectable,

NOTE Confidence: 0.882954597

00:04:40.930 --> 00:04:43.174 patient or patient that is going

NOTE Confidence: 0.882954597

00:04:43.174 --> 00:04:44.670 to receive neoadjuvant therapy

NOTE Confidence: 0.882954597

00:04:44.737 --> 00:04:46.501 with metastatic disease prior

NOTE Confidence: 0.882954597

00:04:46.501 --> 00:04:47.824 to surgical resection,

NOTE Confidence: 0.882954597

00:04:47.830 --> 00:04:50.161 we often consider the use of systemic

NOTE Confidence: 0.882954597

00:04:50.161 --> 00:04:52.429 chemotherapy and the most common regimens,

NOTE Confidence: 0.882954597

00:04:52.430 --> 00:04:53.837 as many of you are familiar with.

NOTE Confidence: 0.882954597

00:04:53.840 --> 00:04:55.360 May include folfox or folfiri

NOTE Confidence: 0.882954597

00:04:55.360 --> 00:04:56.880 with the consideration of a

NOTE Confidence: 0.882954597

00:04:56.938 --> 00:04:58.698 targeted agents such as berbasis,

NOTE Confidence: 0.882954597

00:04:58.700 --> 00:05:01.165 ma'am or anti EGFR therapy

NOTE Confidence: 0.882954597

00:05:01.165 --> 00:05:04.898 such as PM AB or C tax map.

NOTE Confidence: 0.882954597

00:05:04.900 --> 00:05:06.818 If the patient is rest wild type.

NOTE Confidence: 0.882954597

00:05:06.820 --> 00:05:08.512 If the patients treatment naive if

NOTE Confidence: 0.882954597

00:05:08.512 --> 00:05:10.679 they don't have a right sided tumor,

NOTE Confidence: 0.882954597

00:05:10.680 --> 00:05:13.216 we may want to consider anti EGFR therapy,

NOTE Confidence: 0.882954597

00:05:13.220 --> 00:05:15.299 although that is not my personal preference.

NOTE Confidence: 0.882954597

00:05:15.300 --> 00:05:17.610 I tend to reserve it for further

NOTE Confidence: 0.882954597

00:05:17.610 --> 00:05:20.488 down the line and then full Fox

NOTE Confidence: 0.882954597

00:05:20.488 --> 00:05:22.706 Erie for a patient that is well

NOTE Confidence: 0.882954597

00:05:22.706 --> 00:05:23.870 with good performance status.

NOTE Confidence: 0.882954597

00:05:23.870 --> 00:05:25.892 Fair reasonable file with the high

NOTE Confidence: 0.882954597

00:05:25.892 --> 00:05:28.300 response rate of 65 to 78% and then

NOTE Confidence: 0.882954597

00:05:28.300 --> 00:05:30.330 of course we have our oral agents

NOTE Confidence: 0.882954597

00:05:30.396 --> 00:05:32.446 regorafenib and lonsurf that are

NOTE Confidence: 0.882954597

00:05:32.446 --> 00:05:34.496 currently FDA approved as single

NOTE Confidence: 0.882954597

00:05:34.562 --> 00:05:36.262 agents in the refractory setting

NOTE Confidence: 0.882954597

00:05:36.262 --> 00:05:38.426 and then last but not least,

NOTE Confidence: 0.882954597

00:05:38.426 --> 00:05:40.250 the rare subtypes currently.

NOTE Confidence: 0.882954597

00:05:40.250 --> 00:05:42.735 Our median survival for all stage four

NOTE Confidence: 0.882954597

00:05:42.735 --> 00:05:45.253 patients is roughly 32 to 34 months

NOTE Confidence: 0.882954597

00:05:45.253 --> 00:05:46.988 for the general patient population,

NOTE Confidence: 0.882954597

00:05:46.990 --> 00:05:47.989 but once again,

NOTE Confidence: 0.882954597

00:05:47.989 --> 00:05:49.987 right sided tumors do not appear

NOTE Confidence: 0.882954597

00:05:49.987 --> 00:05:52.158 to fear as well in regards

NOTE Confidence: 0.882954597

00:05:52.158 --> 00:05:54.272 to overall survival for our.

NOTE Confidence: 0.882954597

00:05:54.272 --> 00:05:56.236 Either Rasputin patients and

NOTE Confidence: 0.882954597

00:05:56.236 --> 00:05:59.320 then our right side of patients.

NOTE Confidence: 0.882954597

00:05:59.320 --> 00:06:02.309 And these are the molecular subsets that

NOTE Confidence: 0.882954597

00:06:02.309 --> 00:06:05.119 we've largely been focused on recently.

NOTE Confidence: 0.882954597

00:06:05.120 --> 00:06:07.298 Queiroz is the most common mutations.

NOTE Confidence: 0.882954597

00:06:07.300 --> 00:06:08.412 Majority of our patients,

NOTE Confidence: 0.882954597

00:06:08.412 --> 00:06:11.074 but we do like to take into account other

NOTE Confidence: 0.882954597

00:06:11.074 --> 00:06:13.730 rare RASK mutations such as N Rasen d'etre,

NOTE Confidence: 0.882954597

00:06:13.730 --> 00:06:15.512 and then we do have some

NOTE Confidence: 0.882954597

00:06:15.512 --> 00:06:16.403 other rare mutations,

NOTE Confidence: 0.882954597

00:06:16.410 --> 00:06:17.595 including MSI high,

NOTE Confidence: 0.882954597

00:06:17.595 --> 00:06:20.360 which will be discussing the BRAF mutation,

NOTE Confidence: 0.882954597

00:06:20.360 --> 00:06:22.852 which is less than 10% of our

NOTE Confidence: 0.882954597

00:06:22.852 --> 00:06:24.411 patient population with V600E.

NOTE Confidence: 0.882954597

00:06:24.411 --> 00:06:26.997 PIK 3 CA is being investigated,

NOTE Confidence: 0.882954597

00:06:27.000 --> 00:06:30.120 as in clinical trials and then.

NOTE Confidence: 0.882954597

00:06:30.120 --> 00:06:31.380 And then there's the end track fusion,

NOTE Confidence: 0.882954597

00:06:31.380 --> 00:06:32.808 which I will not be touching upon,

NOTE Confidence: 0.882954597

00:06:32.810 --> 00:06:33.962 because that's extremely rare

NOTE Confidence: 0.882954597

00:06:33.962 --> 00:06:36.118 and have yet to see a patient

NOTE Confidence: 0.882954597

00:06:36.118 --> 00:06:37.606 with the interact fusion.

NOTE Confidence: 0.882954597

00:06:37.610 --> 00:06:39.521 But I'm always curious when people tell

NOTE Confidence: 0.882954597

00:06:39.521 --> 00:06:41.559 me they've had one occasional patient,

NOTE Confidence: 0.882954597

00:06:41.560 --> 00:06:43.488 and that's less than 1% of all patients.

NOTE Confidence: 0.825977781111111

00:06:45.620 --> 00:06:47.768 So for all of our patients

NOTE Confidence: 0.825977781111111

00:06:47.768 --> 00:06:48.842 with metastatic disease,

NOTE Confidence: 0.825977781111111

00:06:48.850 --> 00:06:51.127 I'm going to be focusing on that in large

NOTE Confidence: 0.825977781111111

00:06:51.127 --> 00:06:53.063 part for this talk and then touching

NOTE Confidence: 0.825977781111111

00:06:53.063 --> 00:06:55.030 upon a little bit on early stage,

NOTE Confidence: 0.825977781111111

00:06:55.030 --> 00:06:57.226 colon and rectal if brief time.

NOTE Confidence: 0.825977781111111

00:06:57.230 --> 00:06:59.396 But next generation sequencing is extremely

NOTE Confidence: 0.825977781111111

00:06:59.396 --> 00:07:01.470 important for our patient population,

NOTE Confidence: 0.825977781111111

00:07:01.470 --> 00:07:03.360 and identifying once again those

NOTE Confidence: 0.825977781111111

00:07:03.360 --> 00:07:04.872 mutations that I mentioned.

NOTE Confidence: 0.825977781111111

00:07:04.880 --> 00:07:06.716 And these are some of the

NOTE Confidence: 0.825977781111111

00:07:06.716 --> 00:07:08.310 aspects will be touching upon.

NOTE Confidence: 0.825977781111111

00:07:08.310 --> 00:07:11.268 Once again, MSI Grass B RAF

NOTE Confidence: 0.825977781111111

00:07:11.268 --> 00:07:13.240 and her two amplification.

NOTE Confidence: 0.743948656666667

00:07:15.800 --> 00:07:18.680 For MSI high colorectal carcinoma patients,

NOTE Confidence: 0.743948656666667

00:07:18.680 --> 00:07:20.420 which represent less than 10%

NOTE Confidence: 0.743948656666667

00:07:20.420 --> 00:07:23.300 of our patient population.

NOTE Confidence: 0.743948656666667

00:07:23.300 --> 00:07:25.218 This is one of the most important

NOTE Confidence: 0.743948656666667

00:07:25.218 --> 00:07:27.338 studies to date for MSI high patients,

NOTE Confidence: 0.743948656666667

00:07:27.340 --> 00:07:30.211 and I'm sure many of you are familiar with

NOTE Confidence: 0.743948656666667

00:07:30.211 --> 00:07:32.785 the role of pembrolizumab in treatment.

NOTE Confidence: 0.743948656666667

00:07:32.785 --> 00:07:35.626 Naive MSI high colorectal carcinoma patients.

NOTE Confidence: 0.743948656666667

00:07:35.626 --> 00:07:38.300 This was basically a one to one

NOTE Confidence: 0.743948656666667

00:07:38.371 --> 00:07:40.316 randomization that has since been

NOTE Confidence: 0.743948656666667

00:07:40.316 --> 00:07:42.855 updated in regards to overall survival

NOTE Confidence: 0.743948656666667

00:07:42.855 --> 00:07:44.979 compared to standard chemotherapy,

NOTE Confidence: 0.743948656666667

00:07:44.980 --> 00:07:47.356 and in this case was two primary endpoints,

NOTE Confidence: 0.743948656666667

00:07:47.360 --> 00:07:51.040 PFS and OS, and the results were extremely

NOTE Confidence: 0.743948656666667

00:07:51.040 --> 00:07:53.708 impressive when they were originally.

NOTE Confidence: 0.743948656666667

00:07:53.710 --> 00:07:55.158 Presented and eventually published.

NOTE Confidence: 0.743948656666667

00:07:55.158 --> 00:07:58.172 And this is looking at the progression free

NOTE Confidence: 0.743948656666667

00:07:58.172 --> 00:08:00.909 survival for our MSI high treatment naive

NOTE Confidence: 0.743948656666667

00:08:00.909 --> 00:08:03.226 patients when receiving Pember Lizum app.

NOTE Confidence: 0.743948656666667

00:08:03.230 --> 00:08:05.480 This is single agent pembrolizumab.

NOTE Confidence: 0.743948656666667

00:08:05.480 --> 00:08:08.088 Now you may say that there's a crossover

NOTE Confidence: 0.743948656666667

00:08:08.088 --> 00:08:10.494 in about 1/3 of patients in those that

NOTE Confidence: 0.743948656666667

00:08:10.494 --> 00:08:12.375 did receive Pember Lizum app at 1st and

NOTE Confidence: 0.743948656666667

00:08:12.375 --> 00:08:14.239 did not appear to benefit from this drug.

NOTE Confidence: 0.743948656666667

00:08:14.240 --> 00:08:16.410 And unfortunately we don't have the exact

NOTE Confidence: 0.743948656666667

00:08:16.410 --> 00:08:18.358 etiology to account for this right now.

NOTE Confidence: 0.743948656666667

00:08:18.360 --> 00:08:19.398 But as you can see here,

NOTE Confidence: 0.743948656666667

00:08:19.400 --> 00:08:22.186 the PFS was twice as high for

NOTE Confidence: 0.743948656666667

00:08:22.186 --> 00:08:24.021 that versus standard chemotherapy

NOTE Confidence: 0.743948656666667

00:08:24.021 --> 00:08:26.806 for the majority of patients.

NOTE Confidence: 0.743948656666667

00:08:26.810 --> 00:08:29.967 And the OS has also been determined

NOTE Confidence: 0.743948656666667

00:08:29.967 --> 00:08:32.770 to be of significance in the sense

NOTE Confidence: 0.743948656666667

00:08:32.770 --> 00:08:34.670 that there was crossover loud.

NOTE Confidence: 0.743948656666667

00:08:34.670 --> 00:08:36.886 Once again, this is a Co primary endpoint,

NOTE Confidence: 0.743948656666667

00:08:36.890 --> 00:08:39.823 so 60% of patients were allowed to

NOTE Confidence: 0.743948656666667

00:08:39.823 --> 00:08:41.999 crossover to receive IO therapy,

NOTE Confidence: 0.743948656666667

00:08:42.000 --> 00:08:44.493 and so that that is obviously an issue when

NOTE Confidence: 0.743948656666667

00:08:44.493 --> 00:08:47.246 I'm looking at your statistical significance.

NOTE Confidence: 0.743948656666667

00:08:47.250 --> 00:08:49.150 The prespecified P value

NOTE Confidence: 0.743948656666667

00:08:49.150 --> 00:08:51.441 was supposed to be 0.0246,

NOTE Confidence: 0.743948656666667

00:08:51.441 --> 00:08:54.178 so they did not meet its pre

NOTE Confidence: 0.743948656666667

00:08:54.178 --> 00:08:55.782 specified value for OS,

NOTE Confidence: 0.743948656666667

00:08:55.782 --> 00:08:56.186 however.

NOTE Confidence: 0.743948656666667

00:08:56.186 --> 00:08:59.602 Obviously I would say we can clearly see

NOTE Confidence: 0.743948656666667

00:08:59.602 --> 00:09:02.496 that there was crossover 60% of patients,

NOTE Confidence: 0.743948656666667

00:09:02.496 --> 00:09:04.061 and that's likely accounted for

NOTE Confidence: 0.743948656666667

00:09:04.061 --> 00:09:06.282 this and also keeping in mind this

NOTE Confidence: 0.743948656666667

00:09:06.282 --> 00:09:07.817 is really considered the standard

NOTE Confidence: 0.743948656666667

00:09:07.817 --> 00:09:09.477 of care for these patients.

NOTE Confidence: 0.743948656666667

00:09:09.480 --> 00:09:12.162 Now what is the other 1/3 of patients that

NOTE Confidence: 0.743948656666667

00:09:12.162 --> 00:09:15.056 do not appear to benefit from IO therapy?

NOTE Confidence: 0.743948656666667

00:09:15.060 --> 00:09:15.710 Once again,

NOTE Confidence: 0.743948656666667

00:09:15.710 --> 00:09:18.652 we still have yet to understand why that is,

NOTE Confidence: 0.743948656666667

00:09:18.652 --> 00:09:21.046 and obviously it does bring to mind

NOTE Confidence: 0.743948656666667

00:09:21.046 --> 00:09:23.594 that is there a potential benefit for

NOTE Confidence: 0.743948656666667

00:09:23.594 --> 00:09:25.360 the consideration of chemotherapy,

NOTE Confidence: 0.743948656666667

00:09:25.360 --> 00:09:26.683 plus IO therapy?

NOTE Confidence: 0.743948656666667

00:09:26.683 --> 00:09:30.599 And that is an ongoing trial by the way.

NOTE Confidence: 0.743948656666667

00:09:30.600 --> 00:09:31.788 Looking at response rate,

NOTE Confidence: 0.743948656666667

00:09:31.788 --> 00:09:35.952 you can see here 44% versus 33% for

NOTE Confidence: 0.743948656666667

00:09:35.952 --> 00:09:38.924 pembrolizumab versus standard chemotherapy.

NOTE Confidence: 0.743948656666667

00:09:38.930 --> 00:09:40.748 But what is of great interest?

NOTE Confidence: 0.743948656666667

00:09:40.750 --> 00:09:43.180 I think for many of us is the fact

NOTE Confidence: 0.743948656666667

00:09:43.180 --> 00:09:45.215 that there may be some potential

NOTE Confidence: 0.743948656666667

00:09:45.215 --> 00:09:46.627 benefit for combination therapy.

NOTE Confidence: 0.743948656666667

00:09:46.630 --> 00:09:48.485 Now this is a single ARM study,

NOTE Confidence: 0.743948656666667

00:09:48.490 --> 00:09:53.124 Checkmate 142 looking at Nebo plus iffy.

NOTE Confidence: 0.743948656666667

00:09:53.130 --> 00:09:55.923 It was part of a large study

NOTE Confidence: 0.743948656666667

00:09:55.923 --> 00:09:58.789 that we're not comparative arms,

NOTE Confidence: 0.743948656666667

00:09:58.790 --> 00:10:00.490 but looking at various cohorts,

NOTE Confidence: 0.743948656666667

00:10:00.490 --> 00:10:02.182 and this was in the treatment

NOTE Confidence: 0.743948656666667

00:10:02.182 --> 00:10:03.028 naive setting here,

NOTE Confidence: 0.743948656666667

00:10:03.030 --> 00:10:05.984 primary endpoint was response and this was

NOTE Confidence: 0.743948656666667

00:10:05.984 --> 00:10:09.690 published by Heinz Josef Lenz last fall,

NOTE Confidence: 0.743948656666667

00:10:09.690 --> 00:10:11.770 and I told you the response rate was

NOTE Confidence: 0.743948656666667

00:10:11.770 --> 00:10:13.670 44% for single agent pembrolizumab.

NOTE Confidence: 0.743948656666667

00:10:13.670 --> 00:10:15.392 Keeping in mind this is once

NOTE Confidence: 0.743948656666667

00:10:15.392 --> 00:10:17.176 again a small study, 45 patients.

NOTE Confidence: 0.743948656666667

00:10:17.176 --> 00:10:19.084 This is not a phase three,

NOTE Confidence: 0.743948656666667

00:10:19.090 --> 00:10:21.762 but the response rate was 69% and

NOTE Confidence: 0.743948656666667

00:10:21.762 --> 00:10:23.694 as you can see across the board.

NOTE Confidence: 0.900595142222222

00:10:23.700 --> 00:10:26.700 Quite impressive response rates and they

NOTE Confidence: 0.900595142222222

00:10:26.700 --> 00:10:31.414 reported that the 24 month of OS was 79%,

NOTE Confidence: 0.900595142222222

00:10:31.414 --> 00:10:32.884 so it's actually quite impressive

NOTE Confidence: 0.900595142222222

00:10:32.884 --> 00:10:34.850 and obviously I think many of us

NOTE Confidence: 0.900595142222222

00:10:34.850 --> 00:10:36.320 look forward to learning more about

NOTE Confidence: 0.900595142222222

00:10:36.320 --> 00:10:37.658 the benefit of combination therapy

NOTE Confidence: 0.900595142222222

00:10:37.658 --> 00:10:39.713 and see if it is truly superior.

NOTE Confidence: 0.900595142222222

00:10:39.713 --> 00:10:43.164 But once again, Pember Lizum app has

NOTE Confidence: 0.900595142222222

00:10:43.164 --> 00:10:46.010 demonstrated this in a phase three trial.

NOTE Confidence: 0.900595142222222

00:10:46.010 --> 00:10:47.880 What are the ongoing trials?

NOTE Confidence: 0.900595142222222

00:10:47.880 --> 00:10:51.642 So there is a stage three trials called

NOTE Confidence: 0.900595142222222

00:10:51.642 --> 00:10:54.630 Atomic, which is folfox plus or minus 8 SO.

NOTE Confidence: 0.900595142222222

00:10:54.630 --> 00:10:55.830 And then, as I mentioned before,

NOTE Confidence: 0.900595142222222

00:10:55.830 --> 00:10:57.270 there is a combo study that

NOTE Confidence: 0.900595142222222

00:10:57.270 --> 00:10:58.890 was very slow to enrollment.

NOTE Confidence: 0.900595142222222

00:10:58.890 --> 00:11:00.265 Hopefully will it will finish

NOTE Confidence: 0.900595142222222

00:11:00.265 --> 00:11:02.010 enrollment at some point called commit.

NOTE Confidence: 0.900595142222222

00:11:02.010 --> 00:11:04.440 Looking at Folfox plus Bev.

NOTE Confidence: 0.900595142222222

00:11:04.440 --> 00:11:05.460 And then it has,

NOTE Confidence: 0.900595142222222

00:11:05.460 --> 00:11:07.330 oh there is a Merc platform study

NOTE Confidence: 0.900595142222222

00:11:07.330 --> 00:11:09.546 that is also new and ongoing as well.

NOTE Confidence: 0.900595142222222

00:11:09.550 --> 00:11:11.548 And in rectal cancer there's actually

NOTE Confidence: 0.900595142222222

00:11:11.548 --> 00:11:13.240 some very intriguing data regarding

NOTE Confidence: 0.900595142222222

00:11:13.240 --> 00:11:15.368 MSI high and that was just reported.

NOTE Confidence: 0.900595142222222

00:11:15.370 --> 00:11:18.140 So we'll touch upon that.

NOTE Confidence: 0.900595142222222

00:11:18.140 --> 00:11:20.258 So obviously the results from Pember

NOTE Confidence: 0.900595142222222

00:11:20.258 --> 00:11:22.512 Lism AB are quite impressive and

NOTE Confidence: 0.900595142222222

00:11:22.512 --> 00:11:24.828 and there was another pilot trial

NOTE Confidence: 0.900595142222222

00:11:24.828 --> 00:11:27.302 called the Niche trial looking at a

NOTE Confidence: 0.900595142222222

00:11:27.302 --> 00:11:29.492 very very small number of MSI high

NOTE Confidence: 0.900595142222222

00:11:29.492 --> 00:11:31.148 patients and looking at the role

NOTE Confidence: 0.900595142222222

00:11:31.148 --> 00:11:32.950 MSI and MSI stable patients looking

NOTE Confidence: 0.900595142222222

00:11:32.950 --> 00:11:35.110 at the role new Advent IO therapy

NOTE Confidence: 0.900595142222222

00:11:35.110 --> 00:11:36.964 in that setting and they noticed

NOTE Confidence: 0.900595142222222

00:11:36.964 --> 00:11:38.624 there was some significant benefit.

NOTE Confidence: 0.900595142222222

00:11:38.624 --> 00:11:41.520 So why not consider that in an MSI

NOTE Confidence: 0.900595142222222

00:11:41.594 --> 00:11:43.254 high rectal patient population

00:11:43.254 --> 00:11:45.744 and this trial was actually just

00:11:45.815 --> 00:11:48.188 presented by Doctor Loomis who is a.

00:11:48.190 --> 00:11:50.572 Fellow at Memorial Sloan Kettering under

00:11:50.572 --> 00:11:53.640 the guidance of my friend Andrea Sirsak.

00:11:53.640 --> 00:11:55.896 They're looking at the star lamat,

00:11:55.900 --> 00:11:58.282 so here locally advanced MSI high

00:11:58.282 --> 00:12:00.779 rectal cancer stage two stage three.

00:12:00.780 --> 00:12:03.377 They gave six months of Dystar lemon

00:12:03.380 --> 00:12:05.732 and then they wanted to look at

00:12:05.732 --> 00:12:07.724 basically their response by endoscopy

00:12:07.724 --> 00:12:10.520 as well as by imaging and the

00:12:10.520 --> 00:12:12.320 primary end point here is response.

00:12:12.320 --> 00:12:14.721 Now be results from this trial were

00:12:14.721 --> 00:12:17.241 so impressive that they decided to go

00:12:17.241 --> 00:12:19.377 ahead and provide the presentation on

00:12:19.441 --> 00:12:21.913 the 1st 11 out of 16 patients enrolled.

NOTE Confidence: 0.900595142222222

00:12:21.920 --> 00:12:24.506 The total number of patients expect.

NOTE Confidence: 0.900595142222222

00:12:24.510 --> 00:12:28.290 Roll and roll in. This trial is 30 patients.

NOTE Confidence: 0.900595142222222

00:12:28.290 --> 00:12:29.991 And here is what they call clinical

NOTE Confidence: 0.900595142222222

00:12:29.991 --> 00:12:30.477 complete response.

NOTE Confidence: 0.900595142222222

00:12:30.480 --> 00:12:33.030 Once again is the endoscopic CR

NOTE Confidence: 0.900595142222222

00:12:33.030 --> 00:12:35.589 plus the radiographic CR and they

NOTE Confidence: 0.900595142222222

00:12:35.589 --> 00:12:38.305 required all patients to have an MRI.

NOTE Confidence: 0.900595142222222

00:12:38.310 --> 00:12:40.008 And this was the patient population.

NOTE Confidence: 0.900595142222222

00:12:40.010 --> 00:12:41.426 Just to give you an idea real quick,

NOTE Confidence: 0.900595142222222

00:12:41.430 --> 00:12:43.420 I'm just going to touch up on the key points.

NOTE Confidence: 0.900595142222222

00:12:43.420 --> 00:12:45.946 A lot of patients were T3T4 a lot

NOTE Confidence: 0.900595142222222

00:12:45.946 --> 00:12:47.406 of patients were node positive.

NOTE Confidence: 0.900595142222222

00:12:47.410 --> 00:12:49.554 These were MSI high,

NOTE Confidence: 0.900595142222222

00:12:49.554 --> 00:12:52.770 but all were BRAF wild type.

NOTE Confidence: 0.900595142222222

00:12:52.770 --> 00:12:54.828 And this is the very early results.

NOTE Confidence: 0.900595142222222

00:12:54.830 --> 00:12:56.545 We do not have long term results,

NOTE Confidence: 0.900595142222222

00:12:56.550 --> 00:12:58.832 just early results of the 1st 11

NOTE Confidence: 0.900595142222222

00:12:58.832 --> 00:13:01.318 patients out of the 16 enrolled this

NOTE Confidence: 0.900595142222222

00:13:01.318 --> 00:13:03.750 far and they reported a complete CR.

NOTE Confidence: 0.900595142222222

00:13:03.750 --> 00:13:06.214 And in this study in fact they omitted

NOTE Confidence: 0.900595142222222

00:13:06.214 --> 00:13:08.268 the consideration of radiation and surgery.

NOTE Confidence: 0.900595142222222

00:13:08.270 --> 00:13:11.024 So do keep that in mind in this

NOTE Confidence: 0.900595142222222

00:13:11.024 --> 00:13:11.898 patient population.

NOTE Confidence: 0.900595142222222

00:13:11.898 --> 00:13:13.646 Obviously single institution study

NOTE Confidence: 0.900595142222222

00:13:13.646 --> 00:13:15.956 we need more follow up and I'd

NOTE Confidence: 0.900595142222222

00:13:15.956 --> 00:13:17.960 like to see this data validated

NOTE Confidence: 0.8154273212

00:13:17.960 --> 00:13:19.104 now in Full disclosure.

NOTE Confidence: 0.8154273212

00:13:19.104 --> 00:13:21.398 Kristen See Amber who I'm helping to mentor

NOTE Confidence: 0.8154273212

00:13:21.398 --> 00:13:23.486 and I worked with her extensively on this.

NOTE Confidence: 0.8154273212

00:13:23.490 --> 00:13:26.700 Protocol we had actually created this

NOTE Confidence: 0.8154273212

00:13:26.700 --> 00:13:28.946 national trial supported by Ekaki,

NOTE Confidence: 0.8154273212

00:13:28.946 --> 00:13:31.690 a 2201 looking at New Advent Niveau

NOTE Confidence: 0.8154273212

00:13:31.769 --> 00:13:34.317 EP also in the MSI high patient

NOTE Confidence: 0.8154273212

00:13:34.317 --> 00:13:36.441 population with the consideration of

NOTE Confidence: 0.8154273212

00:13:36.441 --> 00:13:39.806 five by five radiation therapy and then

NOTE Confidence: 0.8154273212

00:13:39.806 --> 00:13:42.221 also the consideration of sphincter

NOTE Confidence: 0.8154273212

00:13:42.221 --> 00:13:44.190 preservation here primary endpoint was

NOTE Confidence: 0.8154273212

00:13:44.190 --> 00:13:46.803 Patsy R because the findings from Asco

NOTE Confidence: 0.8154273212

00:13:46.803 --> 00:13:49.406 GI from Doctor Loomis this trial is

NOTE Confidence: 0.8154273212

00:13:49.406 --> 00:13:51.998 going to undergo some rapid amendment

NOTE Confidence: 0.8154273212

00:13:52.000 --> 00:13:54.590 to maybe allow the consideration.

NOTE Confidence: 0.8154273212

00:13:54.590 --> 00:13:58.048 Of not necessarily requiring 5 by 5

NOTE Confidence: 0.8154273212

00:13:58.048 --> 00:14:00.657 radiation therapy unless there's bulky

NOTE Confidence: 0.8154273212

00:14:00.657 --> 00:14:02.628 tumor and adenopathy and obviously

NOTE Confidence: 0.8154273212

00:14:02.628 --> 00:14:04.438 once again it's very interesting

NOTE Confidence: 0.8154273212

00:14:04.438 --> 00:14:06.494 'cause we actually recommended the

NOTE Confidence: 0.8154273212

00:14:06.494 --> 00:14:08.134 consideration of making sphincter

NOTE Confidence: 0.8154273212

00:14:08.134 --> 00:14:10.019 preservation as a primary endpoint.

NOTE Confidence: 0.8154273212

00:14:10.020 --> 00:14:12.400 But when we originally wrote this trial,

NOTE Confidence: 0.8154273212

00:14:12.400 --> 00:14:14.336 we were told that that was being too

NOTE Confidence: 0.8154273212

00:14:14.336 --> 00:14:15.751 progressive and here we are today

NOTE Confidence: 0.8154273212

00:14:15.751 --> 00:14:17.490 trying to amend this trial to keep up.

NOTE Confidence: 0.8154273212

00:14:17.490 --> 00:14:18.315 But once again,

NOTE Confidence: 0.8154273212

00:14:18.315 --> 00:14:20.240 this is a national trial and we

NOTE Confidence: 0.8154273212

00:14:20.307 --> 00:14:22.316 will remain open and we hope to

NOTE Confidence: 0.8154273212

00:14:22.316 --> 00:14:24.174 enroll these patients once again.

NOTE Confidence: 0.8154273212

00:14:24.174 --> 00:14:25.886 Pilot study of roughly.

NOTE Confidence: 0.8154273212

00:14:25.890 --> 00:14:28.918 31 patients as well.

NOTE Confidence: 0.8154273212

00:14:28.920 --> 00:14:31.120 What about our Brafman patients?

NOTE Confidence: 0.8154273212

00:14:31.120 --> 00:14:31.480 Well,

NOTE Confidence: 0.8154273212

00:14:31.480 --> 00:14:34.360 for our MSI stable be wrapping in patients,

NOTE Confidence: 0.8154273212

00:14:34.360 --> 00:14:36.100 it's very poor prognostic

NOTE Confidence: 0.8154273212

00:14:36.100 --> 00:14:37.840 factor for these patients.

NOTE Confidence: 0.8154273212

00:14:37.840 --> 00:14:40.280 It's less than 9% of our patient population.

NOTE Confidence: 0.8154273212

00:14:40.280 --> 00:14:41.068 Unlike Melanoma,

NOTE Confidence: 0.8154273212

00:14:41.068 --> 00:14:42.644 single agent Byref inhibitors

NOTE Confidence: 0.8154273212

00:14:42.644 --> 00:14:44.554 have not been impressive with

NOTE Confidence: 0.8154273212

00:14:44.554 --> 00:14:46.216 response rate of less than 5%,

NOTE Confidence: 0.8154273212

00:14:46.220 --> 00:14:49.244 and we noted that there were basically

NOTE Confidence: 0.8154273212

00:14:49.244 --> 00:14:51.610 escape mechanisms in colorectal cancer in

NOTE Confidence: 0.8154273212

00:14:51.610 --> 00:14:54.270 comparison to the success that was seen

NOTE Confidence: 0.8154273212

00:14:54.270 --> 00:14:56.172 in Melanoma with standard chemotherapy,

NOTE Confidence: 0.8154273212

00:14:56.172 --> 00:14:57.788 the median overall survival

NOTE Confidence: 0.8154273212

00:14:57.788 --> 00:14:59.859 is only 12 to 14 months.

NOTE Confidence: 0.8154273212

00:14:59.860 --> 00:15:01.360 And So what can we do?

NOTE Confidence: 0.8154273212

00:15:01.360 --> 00:15:03.472 How can we basically not only

NOTE Confidence: 0.8154273212

00:15:03.472 --> 00:15:05.780 utilize our B RAF inhibitors?

NOTE Confidence: 0.8154273212

00:15:05.780 --> 00:15:08.126 But how can we also consideration

NOTE Confidence: 0.8154273212

00:15:08.126 --> 00:15:09.299 other downstream impact?

NOTE Confidence: 0.8154273212

00:15:09.300 --> 00:15:12.016 And so here we have the combination.

NOTE Confidence: 0.8154273212

00:15:12.020 --> 00:15:12.980 Basically with Ralph,

NOTE Confidence: 0.8154273212

00:15:12.980 --> 00:15:15.220 Egypt are and then there was an

NOTE Confidence: 0.8154273212

00:15:15.285 --> 00:15:17.220 attempt in combination with Mac.

NOTE Confidence: 0.8154273212

00:15:17.220 --> 00:15:18.700 This was the B control,

NOTE Confidence: 0.8154273212

00:15:18.700 --> 00:15:21.508 so the B control had a triplet versus the

NOTE Confidence: 0.8154273212

00:15:21.508 --> 00:15:23.738 doublet versus standard chemotherapy.

NOTE Confidence: 0.8154273212

00:15:23.740 --> 00:15:25.906 For patients that have received at

NOTE Confidence: 0.8154273212

00:15:25.906 --> 00:15:28.032 least one prior line of therapy

NOTE Confidence: 0.8154273212

00:15:28.032 --> 00:15:29.636 for B RAF meeting V.

NOTE Confidence: 0.8154273212

00:15:29.636 --> 00:15:29.960 600.

NOTE Confidence: 0.8154273212

00:15:29.960 --> 00:15:32.126 Mutation and the doublet was determined

NOTE Confidence: 0.8154273212

00:15:32.126 --> 00:15:35.407 to be just as successful as the triplet,

NOTE Confidence: 0.8154273212

00:15:35.410 --> 00:15:36.780 and this was FDA approved.

NOTE Confidence: 0.8154273212

00:15:36.780 --> 00:15:39.996 This is the regimen called B raft OD,

NOTE Confidence: 0.8154273212

00:15:40.000 --> 00:15:42.403 and it resulted in OS of nine point 3

NOTE Confidence: 0.8154273212

00:15:42.403 --> 00:15:44.488 months versus standard chemotherapy.

NOTE Confidence: 0.8154273212

00:15:44.490 --> 00:15:45.875 Now what's really interesting is

NOTE Confidence: 0.8154273212

00:15:45.875 --> 00:15:47.564 they decided to examine that regimen

NOTE Confidence: 0.8154273212

00:15:47.564 --> 00:15:49.314 because it seemed to be the most

NOTE Confidence: 0.8154273212

00:15:49.314 --> 00:15:50.910 successful and try to move it up

NOTE Confidence: 0.8154273212

00:15:50.910 --> 00:15:52.258 front to the treatment naive setting.

NOTE Confidence: 0.8154273212

00:15:52.258 --> 00:15:54.642 And this is the anchor trial which was

NOTE Confidence: 0.8154273212

00:15:54.642 --> 00:15:56.435 reported at ESMO and I show it here.

NOTE Confidence: 0.8154273212

00:15:56.440 --> 00:15:58.568 'cause this has since been updated as well.

NOTE Confidence: 0.8154273212

00:15:58.570 --> 00:16:00.318 At ESMO last year.

NOTE Confidence: 0.8154273212

00:16:00.318 --> 00:16:02.940 And they reported a response rate

NOTE Confidence: 0.8154273212

00:16:03.027 --> 00:16:04.119 of about 50%.

NOTE Confidence: 0.8154273212

00:16:04.120 --> 00:16:07.168 However, the PFS was only about four months,

00:16:07.170 --> 00:16:09.954 and so that was clearly not a home

00:16:09.954 --> 00:16:12.897 run for a treatment naive patient.

00:16:12.900 --> 00:16:15.322 So at this year's Oscar GI just

00:16:15.322 --> 00:16:17.174 a couple weeks ago, Dan Morris,

00:16:17.174 --> 00:16:18.476 so I'm so very proud of.

00:16:18.480 --> 00:16:20.592 From MD Anderson has completed this

00:16:20.592 --> 00:16:23.130 pilot trial at MD Anderson looking at

00:16:23.130 --> 00:16:25.974 end crafted and so text amount so the

00:16:25.974 --> 00:16:28.422 beer F to V but in combination with

00:16:28.422 --> 00:16:29.732 immune checkpoint inhibition with

00:16:29.732 --> 00:16:32.070 nivolumab in this setting and this is

00:16:32.130 --> 00:16:33.918 in previously treated patients and the

00:16:33.918 --> 00:16:36.140 reason for that is because there appears

00:16:36.140 --> 00:16:38.275 to be a higher immune activation and

00:16:38.275 --> 00:16:40.520 higher team be in this patient population.

00:16:40.520 --> 00:16:42.284 And as you know some of the

NOTE Confidence: 0.684076439

00:16:42.284 --> 00:16:43.640 B RAF subtypes actually.

NOTE Confidence: 0.684076439

00:16:43.640 --> 00:16:46.058 Are very similar to this one.

NOTE Confidence: 0.684076439

00:16:46.060 --> 00:16:48.756 So more likely to respond to IO therapy,

NOTE Confidence: 0.684076439

00:16:48.760 --> 00:16:51.480 single institution study, small numbers,

NOTE Confidence: 0.684076439

00:16:51.480 --> 00:16:53.570 important to keep in mind.

NOTE Confidence: 0.684076439

00:16:53.570 --> 00:16:55.718 And here's the primary endpoint response,

NOTE Confidence: 0.684076439

00:16:55.720 --> 00:16:57.088 and these were the doses that

NOTE Confidence: 0.684076439

00:16:57.088 --> 00:16:58.440 were provided to these patients.

NOTE Confidence: 0.684076439

00:16:58.440 --> 00:17:00.624 Keeping in mind these patients need a

NOTE Confidence: 0.684076439

00:17:00.624 --> 00:17:02.840 better option as they just showed you,

NOTE Confidence: 0.684076439

00:17:02.840 --> 00:17:04.820 they don't do well with standard

NOTE Confidence: 0.684076439

00:17:04.820 --> 00:17:05.480 chemotherapy therapy,

NOTE Confidence: 0.684076439

00:17:05.480 --> 00:17:08.738 and even with RAF target therapy,

NOTE Confidence: 0.684076439

00:17:08.740 --> 00:17:12.076 they still need a better response.

NOTE Confidence: 0.684076439

00:17:12.080 --> 00:17:13.796 So once again,

NOTE Confidence: 0.684076439

00:17:13.796 --> 00:17:16.656 single institution very thought provoking.

NOTE Confidence: 0.684076439

00:17:16.660 --> 00:17:18.916 They report a response rate 50%

NOTE Confidence: 0.684076439

00:17:18.920 --> 00:17:21.083 so not much higher than what was

NOTE Confidence: 0.684076439

00:17:21.083 --> 00:17:23.020 already reported in the prior study.

NOTE Confidence: 0.684076439

00:17:23.020 --> 00:17:23.357 However,

NOTE Confidence: 0.684076439

00:17:23.357 --> 00:17:26.406 the PFS was a little bit higher at 7.4

NOTE Confidence: 0.684076439

00:17:26.406 --> 00:17:28.752 months, and the OS was 15.1 months.

NOTE Confidence: 0.684076439

00:17:28.752 --> 00:17:30.894 This is after a medium fault time

NOTE Confidence: 0.684076439

00:17:30.894 --> 00:17:31.889 of 16 months.

NOTE Confidence: 0.684076439

00:17:31.890 --> 00:17:33.850 Now these results were impressive

NOTE Confidence: 0.684076439

00:17:33.850 --> 00:17:36.534 enough that now this is going to

NOTE Confidence: 0.684076439

00:17:36.534 --> 00:17:38.888 be a national trial swab 2107 with

NOTE Confidence: 0.684076439

00:17:38.888 --> 00:17:41.810 a 2 to one randomization of the

NOTE Confidence: 0.684076439

00:17:41.810 --> 00:17:43.460 addition of BIOTHERAPY.

NOTE Confidence: 0.684076439

00:17:43.460 --> 00:17:45.749 At a study less than 75 patients,

NOTE Confidence: 0.684076439

00:17:45.750 --> 00:17:47.350 this should be opening up.

NOTE Confidence: 0.684076439

00:17:47.350 --> 00:17:48.058 This is March,

NOTE Confidence: 0.684076439

00:17:48.058 --> 00:17:49.710 so it should be opening up at

NOTE Confidence: 0.684076439

00:17:49.770 --> 00:17:51.680 the latter part of April and we

NOTE Confidence: 0.684076439

00:17:51.680 --> 00:17:53.230 are excited about this trial.

NOTE Confidence: 0.684076439

00:17:53.230 --> 00:17:56.245 It allows one to two prior lines of therapy,

NOTE Confidence: 0.684076439

00:17:56.250 --> 00:17:57.910 so that's in your previously

NOTE Confidence: 0.684076439

00:17:57.910 --> 00:17:58.906 treated brip patients.

NOTE Confidence: 0.684076439

00:17:58.910 --> 00:18:00.550 If you have any patient

NOTE Confidence: 0.684076439

00:18:00.550 --> 00:18:02.170 starting in the next two months,

NOTE Confidence: 0.684076439

00:18:02.170 --> 00:18:03.670 please consider this trial when

NOTE Confidence: 0.684076439

00:18:03.670 --> 00:18:05.936 it is open at time to activate

NOTE Confidence: 0.684076439

00:18:05.936 --> 00:18:07.336 it at your institution.

NOTE Confidence: 0.684076439

00:18:07.340 --> 00:18:10.147 Now there is a phase three trial

NOTE Confidence: 0.684076439

00:18:10.147 --> 00:18:12.352 that is ongoing for these patients

NOTE Confidence: 0.684076439

00:18:12.352 --> 00:18:14.690 and I also want to highlight this

NOTE Confidence: 0.684076439

00:18:14.756 --> 00:18:17.136 because it is the only phase three

NOTE Confidence: 0.684076439

00:18:17.136 --> 00:18:19.190 trial in treatment naive patients.

NOTE Confidence: 0.684076439

00:18:19.190 --> 00:18:24.563 So this is a one to one to one

NOTE Confidence: 0.684076439

00:18:24.563 --> 00:18:26.930 randomization of basically beer after V.

NOTE Confidence: 0.684076439

00:18:26.930 --> 00:18:27.950 So end carafe,

NOTE Confidence: 0.684076439

00:18:27.950 --> 00:18:30.148 and if the BRAF inhibitor plus the

NOTE Confidence: 0.684076439

00:18:30.148 --> 00:18:32.512 text map or that same combination

NOTE Confidence: 0.684076439

00:18:32.512 --> 00:18:34.677 be wrapped heavy plus folfox,

NOTE Confidence: 0.684076439

00:18:34.680 --> 00:18:35.848 they've actually decided not

NOTE Confidence: 0.684076439

00:18:35.848 --> 00:18:37.308 to proceed with full fury.

NOTE Confidence: 0.684076439

00:18:37.310 --> 00:18:39.038 That was part of the run in phase

NOTE Confidence: 0.684076439

00:18:39.038 --> 00:18:40.668 and so does now with Folfox.

NOTE Confidence: 0.684076439

00:18:40.670 --> 00:18:42.830 This phase three arm just opened

NOTE Confidence: 0.684076439

00:18:42.830 --> 00:18:45.635 about two weeks ago and then the

NOTE Confidence: 0.684076439

00:18:45.635 --> 00:18:47.795 control arm is standard chemotherapy,

NOTE Confidence: 0.684076439

00:18:47.800 --> 00:18:49.809 so this trial is largely being run

NOTE Confidence: 0.684076439

00:18:49.809 --> 00:18:52.049 in Europe and they're about 9 sites.

NOTE Confidence: 0.684076439

00:18:52.050 --> 00:18:53.922 The last time I checked in the United States,

NOTE Confidence: 0.684076439

00:18:53.930 --> 00:18:55.351 we are one of the sites that

NOTE Confidence: 0.684076439

00:18:55.351 --> 00:18:56.460 are participating in this trial.

NOTE Confidence: 0.684076439

00:18:56.460 --> 00:18:57.000 Once again,

NOTE Confidence: 0.684076439

00:18:57.000 --> 00:18:58.890 we really need to find an option

NOTE Confidence: 0.684076439

00:18:58.890 --> 00:19:00.830 for these patients with very

NOTE Confidence: 0.684076439

00:19:00.830 --> 00:19:02.036 poor prognosis otherwise,

NOTE Confidence: 0.684076439

00:19:02.040 --> 00:19:04.455 so please consider enrollment to this trial.

NOTE Confidence: 0.908759585555555

00:19:06.640 --> 00:19:09.097 I wanted to just briefly touch upon her too,

NOTE Confidence: 0.908759585555555

00:19:09.100 --> 00:19:11.236 'cause there's a lot of interest and direct.

NOTE Confidence: 0.908759585555555

00:19:11.240 --> 00:19:13.336 Can I know that many of you are

NOTE Confidence: 0.908759585555555

00:19:13.336 --> 00:19:15.468 familiar with direct can because it is

NOTE Confidence: 0.908759585555555

00:19:15.468 --> 00:19:17.480 proved in gastric and breast cancer,

NOTE Confidence: 0.908759585555555

00:19:17.480 --> 00:19:19.922 but her two positivity is extremely

34

NOTE Confidence: 0.908759585555555

00:19:19.922 --> 00:19:21.550 rare in colorectal cancer,

NOTE Confidence: 0.908759585555555

00:19:21.550 --> 00:19:24.256 unlike a gastric and breast cancer,

NOTE Confidence: 0.908759585555555

00:19:24.260 --> 00:19:26.708 it's about 4% of our patients,

NOTE Confidence: 0.908759585555555

00:19:26.710 --> 00:19:30.350 and once again it is required to be 3 plus

NOTE Confidence: 0.908759585555555

00:19:30.439 --> 00:19:33.516 by IHC or fish amplified and IHC 2 plus.

NOTE Confidence: 0.908759585555555

00:19:33.516 --> 00:19:35.010 So ongoing studies that I will

NOTE Confidence: 0.908759585555555

00:19:35.064 --> 00:19:36.846 not be touching upon 'cause they.

NOTE Confidence: 0.908759585555555

00:19:36.850 --> 00:19:37.564 Finished enrollment,

NOTE Confidence: 0.908759585555555

00:19:37.564 --> 00:19:40.063 but have not yet been reported yet.

NOTE Confidence: 0.908759585555555

00:19:40.070 --> 00:19:41.183 There's swag 1613,

NOTE Confidence: 0.908759585555555

00:19:41.183 --> 00:19:43.409 which is treasure map plus produce

NOTE Confidence: 0.908759585555555

00:19:43.409 --> 00:19:45.808 a map versus standard chemotherapy

NOTE Confidence: 0.908759585555555

00:19:45.808 --> 00:19:48.132 in the previously treated setting,

NOTE Confidence: 0.908759585555555

00:19:48.132 --> 00:19:50.304 and then the Mountaineer study was

NOTE Confidence: 0.908759585555555

00:19:50.304 --> 00:19:52.649 to catnip plus restitution amount.

NOTE Confidence: 0.908759585555555

00:19:52.650 --> 00:19:55.310 Now I'll just be touching on destiny

NOTE Confidence: 0.908759585555555

00:19:55.310 --> 00:19:58.470 because this was a recently updated as well.

NOTE Confidence: 0.908759585555555

00:19:58.470 --> 00:20:00.864 So Destiny is looking at an antibody

NOTE Confidence: 0.908759585555555

00:20:00.864 --> 00:20:01.548 drug conjugate,

NOTE Confidence: 0.908759585555555

00:20:01.550 --> 00:20:03.769 which is direct can and this trial

NOTE Confidence: 0.908759585555555

00:20:03.769 --> 00:20:05.533 it was extremely interesting for

NOTE Confidence: 0.908759585555555

00:20:05.533 --> 00:20:07.771 many of us in colorectal cancer

NOTE Confidence: 0.908759585555555

00:20:07.771 --> 00:20:09.269 because it's number one.

NOTE Confidence: 0.908759585555555

00:20:09.270 --> 00:20:11.447 It's a different type of drug and

NOTE Confidence: 0.908759585555555

00:20:11.447 --> 00:20:13.509 #2 they allowed patients that have

NOTE Confidence: 0.908759585555555

00:20:13.509 --> 00:20:15.627 had prior anti her two therapy.

NOTE Confidence: 0.908759585555555

00:20:15.630 --> 00:20:18.006 You'll see here they provided the

NOTE Confidence: 0.908759585555555

00:20:18.010 --> 00:20:19.991 6.4 milligram per kilogram dose and I

NOTE Confidence: 0.908759585555555

00:20:19.991 --> 00:20:21.674 mention that because there's a second

NOTE Confidence: 0.908759585555555

00:20:21.674 --> 00:20:23.487 study that is also testing the dose.

NOTE Confidence: 0.908759585555555

00:20:23.490 --> 00:20:26.227 Currently that is open and this is

NOTE Confidence: 0.908759585555555

00:20:26.227 --> 00:20:29.145 at Q three weeks you'll see cohort.

NOTE Confidence: 0.908759585555555

00:20:29.145 --> 00:20:31.980 Today is your IHC 3 plus patient

NOTE Confidence: 0.908759585555555

00:20:32.065 --> 00:20:34.050 population or your fish positive

NOTE Confidence: 0.908759585555555

00:20:34.050 --> 00:20:37.424 cohort B is I see two plus and the

NOTE Confidence: 0.908759585555555

00:20:37.424 --> 00:20:39.837 cohort C is IHC one plus primary

NOTE Confidence: 0.908759585555555

00:20:39.837 --> 00:20:41.208 endpoint was response.

NOTE Confidence: 0.908759585555555

00:20:41.208 --> 00:20:43.493 'cause keeping in mind these

NOTE Confidence: 0.908759585555555

00:20:43.493 --> 00:20:45.840 are small patient population.

NOTE Confidence: 0.908759585555555

00:20:45.840 --> 00:20:48.306 And here focusing on Cohort 8,

NOTE Confidence: 0.908759585555555

00:20:48.310 --> 00:20:50.858 that's really where your focus should be.

NOTE Confidence: 0.908759585555555

00:20:50.860 --> 00:20:53.758 53 patients of those 53 patients,

NOTE Confidence: 0.908759585555555

00:20:53.760 --> 00:20:55.372 24 had a response,

NOTE Confidence: 0.908759585555555

00:20:55.372 --> 00:20:57.790 and these were heavily pretreated patients.

NOTE Confidence: 0.908759585555555

00:20:57.790 --> 00:20:59.054 If I recall correctly,

NOTE Confidence: 0.908759585555555

00:20:59.054 --> 00:21:01.751 the median line of therapies was free and

NOTE Confidence: 0.908759585555555

37

00:21:01.751 --> 00:21:05.129 and basically the response rate was 45%.

NOTE Confidence: 0.908759585555555

00:21:05.129 --> 00:21:07.292 So once again it can be provided

NOTE Confidence: 0.908759585555555

00:21:07.292 --> 00:21:08.580 to a patient.

NOTE Confidence: 0.908759585555555

00:21:08.580 --> 00:21:10.560 That's her two positive that

NOTE Confidence: 0.908759585555555

00:21:10.560 --> 00:21:13.239 that is naive to trust its map,

NOTE Confidence: 0.908759585555555

00:21:13.240 --> 00:21:16.390 or it can be provided to a patient that has.

NOTE Confidence: 0.908759585555555

00:21:16.390 --> 00:21:18.175 Had progression of disease which

NOTE Confidence: 0.908759585555555

00:21:18.175 --> 00:21:20.320 has treasuries map and this could

NOTE Confidence: 0.908759585555555

00:21:20.320 --> 00:21:22.399 be an option now very similar to

NOTE Confidence: 0.908759585555555

00:21:22.399 --> 00:21:24.368 the studies in breast and gastric.

NOTE Confidence: 0.908759585555555

00:21:24.370 --> 00:21:25.576 There is a known toxicity as

NOTE Confidence: 0.908759585555555

00:21:25.576 --> 00:21:26.710 many of you are aware,

NOTE Confidence: 0.908759585555555

00:21:26.710 --> 00:21:27.830 with interstitial lung disease,

NOTE Confidence: 0.908759585555555

00:21:27.830 --> 00:21:29.510 which is in less than 10%

NOTE Confidence: 0.908759585555555

00:21:29.510 --> 00:21:30.742 of the patient population,

NOTE Confidence: 0.908759585555555

00:21:30.742 --> 00:21:32.900 but something important to keep in mind.

NOTE Confidence: 0.8280241575

00:21:35.450 --> 00:21:38.434 And then it wanted to touch upon Cara.

NOTE Confidence: 0.8280241575

00:21:38.440 --> 00:21:42.744 So Karas mutation for us in colorectal cancer

NOTE Confidence: 0.8280241575

00:21:42.744 --> 00:21:46.769 has been one of the most common mutations.

NOTE Confidence: 0.8280241575

00:21:46.770 --> 00:21:48.590 Especially when you take into

NOTE Confidence: 0.8280241575

00:21:48.590 --> 00:21:50.046 account your standard crass.

NOTE Confidence: 0.8280241575

00:21:50.050 --> 00:21:51.422 But then you also have your address

NOTE Confidence: 0.8280241575

00:21:51.422 --> 00:21:53.021 and then rest. Which means all

NOTE Confidence: 0.8280241575

00:21:53.021 --> 00:21:54.706 these patients do not benefit.

NOTE Confidence: 0.8280241575

00:21:54.710 --> 00:21:56.902 So that's about 30 to 60% of patients

NOTE Confidence: 0.8280241575

00:21:56.902 --> 00:21:59.394 do not benefit from anti EGFR therapy.

NOTE Confidence: 0.8280241575

00:21:59.400 --> 00:22:01.812 And then recently there's been some

NOTE Confidence: 0.8280241575

00:22:01.812 --> 00:22:03.790 interest looking at drugs that

NOTE Confidence: 0.8280241575

00:22:03.790 --> 00:22:05.869 are specific to the Cross G 12.

NOTE Confidence: 0.8280241575

00:22:05.870 --> 00:22:07.460 The mutation now keeping in

NOTE Confidence: 0.8280241575

00:22:07.460 --> 00:22:09.416 mind this is very, very rare.

NOTE Confidence: 0.8280241575

00:22:09.416 --> 00:22:10.768 In colorectal cancer it's

NOTE Confidence: 0.8280241575

00:22:10.768 --> 00:22:12.945 less than 5% of our patients,

NOTE Confidence: 0.8280241575

00:22:12.945 --> 00:22:15.255 but it is a potential option

NOTE Confidence: 0.8280241575

00:22:15.260 --> 00:22:18.200 now this has been reported,

NOTE Confidence: 0.8280241575

00:22:18.200 --> 00:22:20.304 you probably seen the data already with long,

NOTE Confidence: 0.8280241575

00:22:20.310 --> 00:22:23.334 much more impressive with lung and colon.

NOTE Confidence: 0.8280241575

00:22:23.340 --> 00:22:26.749 Not so impressive as a single agent.

NOTE Confidence: 0.8280241575

00:22:26.750 --> 00:22:28.395 Basically the response rate was

NOTE Confidence: 0.8280241575

00:22:28.395 --> 00:22:30.786 about a little less than 10% and

NOTE Confidence: 0.8280241575

00:22:30.786 --> 00:22:33.316 this was just published recently.

NOTE Confidence: 0.8280241575

00:22:33.320 --> 00:22:36.650 So Teresa is the drug.

NOTE Confidence: 0.8280241575

00:22:36.650 --> 00:22:38.876 Progression free survival was four months.

NOTE Confidence: 0.8280241575

00:22:38.880 --> 00:22:40.788 The medium fall was after this.

NOTE Confidence: 0.8280241575

00:22:40.790 --> 00:22:42.130 After meeting followed 11 months,

NOTE Confidence: 0.8280241575

00:22:42.130 --> 00:22:44.768 the 12 month PFS was only 11% and

NOTE Confidence: 0.8280241575

00:22:44.768 --> 00:22:46.913 now there are obviously looking

NOTE Confidence: 0.8280241575

00:22:46.913 --> 00:22:49.530 at this drug in combination.

NOTE Confidence: 0.8280241575

00:22:49.530 --> 00:22:52.204 So I I look forward to seeing

NOTE Confidence: 0.8280241575

00:22:52.204 --> 00:22:53.900 some of that data.

NOTE Confidence: 0.8280241575

00:22:53.900 --> 00:22:55.237 But I just want to show this,

NOTE Confidence: 0.8280241575

00:22:55.240 --> 00:22:57.520 although not specific to colorectal cancer.

NOTE Confidence: 0.8280241575

00:22:57.520 --> 00:22:58.418 Once again,

NOTE Confidence: 0.8280241575

00:22:58.418 --> 00:23:01.112 this is at aggressive from another

NOTE Confidence: 0.8280241575

00:23:01.112 --> 00:23:03.738 competing company and I wanted to show

NOTE Confidence: 0.8280241575

00:23:03.738 --> 00:23:06.000 this because it was very impressive

NOTE Confidence: 0.8280241575

00:23:06.000 --> 00:23:08.000 in regards to pancreatic cancer.

NOTE Confidence: 0.8280241575

00:23:08.000 --> 00:23:09.998 Once again, the very small numbers,

NOTE Confidence: 0.8280241575

00:23:10.000 --> 00:23:11.155 so I always.

NOTE Confidence: 0.8280241575

00:23:11.155 --> 00:23:13.080 I'm always very hesitant when

NOTE Confidence: 0.8280241575

00:23:13.080 --> 00:23:15.219 I see very early data.

NOTE Confidence: 0.8280241575

00:23:15.220 --> 00:23:17.764 But basically to focus on the

NOTE Confidence: 0.8280241575

00:23:17.764 --> 00:23:20.016 GI patient population and they

NOTE Confidence: 0.8280241575

00:23:20.016 --> 00:23:22.456 reported that there was basically

NOTE Confidence: 0.8280241575

00:23:22.456 --> 00:23:24.536 a response attend in 10 patients.

NOTE Confidence: 0.8280241575

00:23:24.536 --> 00:23:26.626 Five out of those ten had a

NOTE Confidence: 0.8280241575

00:23:26.626 --> 00:23:28.178 response with pancreatic cancer,

NOTE Confidence: 0.8280241575

00:23:28.180 --> 00:23:30.298 which is unheard of as many

NOTE Confidence: 0.8280241575

00:23:30.300 --> 00:23:32.390 can guess because once again,

NOTE Confidence: 0.8280241575

00:23:32.390 --> 00:23:33.980 pancreatic cancer is still remains

NOTE Confidence: 0.8280241575

00:23:33.980 --> 00:23:34.616 a challenge,

NOTE Confidence: 0.8280241575

00:23:34.620 --> 00:23:37.653 and we don't have a lot of novel agents.

NOTE Confidence: 0.8280241575

00:23:37.660 --> 00:23:39.580 This is once again G12C,

NOTE Confidence: 0.8280241575

00:23:39.580 --> 00:23:42.163 which is not the most common RASC

NOTE Confidence: 0.8280241575

00:23:42.163 --> 00:23:43.800 mutation in pancreatic cancer,

NOTE Confidence: 0.8280241575

00:23:43.800 --> 00:23:45.130 but once again could be.

NOTE Confidence: 0.8280241575

00:23:45.130 --> 00:23:45.734 Potentially beneficial,

NOTE Confidence: 0.8280241575

00:23:45.734 --> 00:23:47.848 and then they are looking at it.

NOTE Confidence: 0.8280241575

00:23:47.850 --> 00:23:49.358 Other malignancies very similar

NOTE Confidence: 0.8280241575

00:23:49.358 --> 00:23:52.384 so that to the soeder as they are

NOTE Confidence: 0.8280241575

00:23:52.384 --> 00:23:54.792 looking at it in combination as well.

NOTE Confidence: 0.8280241575

00:23:54.800 --> 00:23:56.340 So just intriguing data from

NOTE Confidence: 0.8280241575

00:23:56.340 --> 00:23:57.572 this year's Oscar GI.

NOTE Confidence: 0.90010964

00:23:59.720 --> 00:24:02.942 I did want to focus on the role of

NOTE Confidence: 0.90010964

00:24:02.942 --> 00:24:05.318 circulating tumor DNA, just very briefly,

NOTE Confidence: 0.90010964

00:24:05.318 --> 00:24:07.248 because there are two ongoing

NOTE Confidence: 0.90010964

00:24:07.248 --> 00:24:09.398 trials and early stage disease,

NOTE Confidence: 0.90010964

00:24:09.400 --> 00:24:11.404 and then there was this trial

NOTE Confidence: 0.90010964

00:24:11.404 --> 00:24:13.440 that was just presented at Asco

NOTE Confidence: 0.90010964

00:24:13.440 --> 00:24:15.015 GI from the Japanese group.

NOTE Confidence: 0.90010964

00:24:15.020 --> 00:24:17.470 Doctor Katata called Circulate Japan

NOTE Confidence: 0.90010964

00:24:17.470 --> 00:24:21.319 and I thought that this was a very very,

NOTE Confidence: 0.90010964

00:24:21.320 --> 00:24:24.155 very important study that should

NOTE Confidence: 0.90010964

43

00:24:24.155 --> 00:24:26.470 receive attention because it

NOTE Confidence: 0.90010964

00:24:26.470 --> 00:24:29.420 looked at basically all stages.

NOTE Confidence: 0.90010964

00:24:29.420 --> 00:24:32.510 Colon rectal cancer resectable stage

NOTE Confidence: 0.90010964

00:24:32.510 --> 00:24:34.786 four they basically obtained pre-op

NOTE Confidence: 0.90010964

00:24:34.786 --> 00:24:36.856 circulating tumor DNA using the

NOTE Confidence: 0.90010964

00:24:36.856 --> 00:24:38.683 signature platform and then they

NOTE Confidence: 0.90010964

00:24:38.683 --> 00:24:40.717 followed the patients at four weeks,

NOTE Confidence: 0.90010964

00:24:40.720 --> 00:24:43.198 12 weeks, 24 and 36 weeks,

NOTE Confidence: 0.90010964

00:24:43.200 --> 00:24:45.510 and so they provided their data

NOTE Confidence: 0.90010964

00:24:45.510 --> 00:24:47.436 regarding the 1st 1000 plus patients

NOTE Confidence: 0.90010964

00:24:47.436 --> 00:24:49.511 that have been enrolled this far in

NOTE Confidence: 0.90010964

00:24:49.511 --> 00:24:51.215 this trial and they've compiled it

NOTE Confidence: 0.90010964

00:24:51.215 --> 00:24:53.280 based upon these three ongoing studies.

NOTE Confidence: 0.90010964

00:24:53.280 --> 00:24:54.430 As you can see here.

NOTE Confidence: 0.548842114

00:24:56.440 --> 00:24:58.890 Like Vega Galaxy and Altair.

NOTE Confidence: 0.853119543571429

00:25:01.010 --> 00:25:03.649 And what it really shows basically where

NOTE Confidence: 0.853119543571429

00:25:03.649 --> 00:25:06.638 we think the field is obviously going.

NOTE Confidence: 0.853119543571429

00:25:06.640 --> 00:25:08.752 Here we have some information for

NOTE Confidence: 0.853119543571429

00:25:08.752 --> 00:25:10.954 stage one through stage four and and

NOTE Confidence: 0.853119543571429

00:25:10.954 --> 00:25:13.104 as you can see here at the disease

NOTE Confidence: 0.853119543571429

00:25:13.104 --> 00:25:15.084 free survival if you're circulating

NOTE Confidence: 0.853119543571429

00:25:15.084 --> 00:25:17.642 tumor and DNA remain negative with

NOTE Confidence: 0.853119543571429

00:25:17.642 --> 00:25:20.072 dramatically different from if you

NOTE Confidence: 0.853119543571429

00:25:20.072 --> 00:25:22.848 remained positive and this is at post-op

NOTE Confidence: 0.853119543571429

00:25:22.850 --> 00:25:27.428 when compared to baseline at 4 weeks.

NOTE Confidence: 0.853119543571429

00:25:27.430 --> 00:25:29.590 And then they continued to look

NOTE Confidence: 0.853119543571429

00:25:29.590 --> 00:25:31.030 at their sequential circulating

NOTE Confidence: 0.853119543571429

00:25:31.087 --> 00:25:33.023 tumor DNA at 4 weeks and 12 weeks.

NOTE Confidence: 0.853119543571429

00:25:33.030 --> 00:25:34.206 And as you can see here,

NOTE Confidence: 0.853119543571429

00:25:34.210 --> 00:25:36.230 obviously if it remain negative,

NOTE Confidence: 0.853119543571429

00:25:36.230 --> 00:25:37.982 that's a very positive benefit in

NOTE Confidence: 0.853119543571429

45

00:25:37.982 --> 00:25:39.670 regards to disease free survival.

00:25:39.670 --> 00:25:41.749 But if you went from negative to

00:25:41.749 --> 00:25:43.383 positive that changed your disease

00:25:43.383 --> 00:25:45.748 free survival from 98% to 63%.

00:25:45.748 --> 00:25:48.870 If you went from positive to negative,

00:25:48.870 --> 00:25:50.565 let's say with attachment chemotherapy

00:25:50.565 --> 00:25:52.598 that improved your disease free survival

00:25:52.598 --> 00:25:54.003 but positive to positive obviously

00:25:54.003 --> 00:25:56.199 was not a good prognostic indicator.

00:25:58.680 --> 00:26:00.787 And this is looking at the role

00:26:00.787 --> 00:26:02.020 of adjuvant chemotherapy here.

00:26:02.020 --> 00:26:04.436 If you have a positive circulating tumor DNA,

00:26:04.440 --> 00:26:05.996 so very intriguing data,

00:26:05.996 --> 00:26:08.740 and probably the largest data to date.

00:26:08.740 --> 00:26:11.386 So it's it's just important to note.

00:26:11.390 --> 00:26:13.014 And once again the purpose of this

NOTE Confidence: 0.875246469090909

00:26:13.014 --> 00:26:14.643 lecture today is kind of give you

NOTE Confidence: 0.875246469090909

00:26:14.643 --> 00:26:15.975 an idea of the existing interest

NOTE Confidence: 0.875246469090909

00:26:16.029 --> 00:26:17.716 on many of the studies that are

NOTE Confidence: 0.875246469090909

00:26:17.716 --> 00:26:20.180 ongoing in colorectal cancer,

NOTE Confidence: 0.875246469090909

00:26:20.180 --> 00:26:23.050 so I apologize I missed.

NOTE Confidence: 0.9349497

00:26:26.000 --> 00:26:28.652 I apologize. There it is.

NOTE Confidence: 0.9349497

00:26:28.652 --> 00:26:29.800 OK, I was on the right track.

NOTE Confidence: 0.9349497

00:26:29.800 --> 00:26:32.114 I thought I didn't include this slide so

NOTE Confidence: 0.9349497

00:26:32.114 --> 00:26:34.940 currently and as many of you that know me,

NOTE Confidence: 0.9349497

00:26:34.940 --> 00:26:37.538 I'm heavily involved in the NC

NOTE Confidence: 0.9349497

00:26:37.540 --> 00:26:39.796 cooperative groups with swag and ACOG,

NOTE Confidence: 0.9349497

00:26:39.800 --> 00:26:42.026 and especially with my role now on

NOTE Confidence: 0.9349497

00:26:42.026 --> 00:26:44.430 the GI Steering Committee and very

NOTE Confidence: 0.9349497

00:26:44.430 --> 00:26:46.735 supportive of cooperative group trials.

NOTE Confidence: 0.9349497

00:26:46.740 --> 00:26:49.162 So this is the COBRA trial looking

NOTE Confidence: 0.9349497

00:26:49.162 --> 00:26:51.198 specifically at stage 2 colon cancer.

NOTE Confidence: 0.9349497

00:26:51.200 --> 00:26:52.060 As many of you know,

NOTE Confidence: 0.9349497

00:26:52.060 --> 00:26:53.800 for stage 2 colon cancer,

NOTE Confidence: 0.9349497

00:26:53.800 --> 00:26:56.554 as long as I was in fellowship till now,

NOTE Confidence: 0.9349497

00:26:56.560 --> 00:26:58.054 it's always been a discussion with

NOTE Confidence: 0.9349497

00:26:58.054 --> 00:26:59.450 the patient about the role of.

NOTE Confidence: 0.9349497

00:26:59.450 --> 00:27:01.030 Management chemotherapy 'cause it's

NOTE Confidence: 0.9349497

00:27:01.030 --> 00:27:03.836 never been really well defined and has

NOTE Confidence: 0.9349497

00:27:03.836 --> 00:27:05.352 not been statistically significant

NOTE Confidence: 0.9349497

00:27:05.352 --> 00:27:07.474 thus far in any prospective trials.

NOTE Confidence: 0.9349497

00:27:07.474 --> 00:27:10.232 So here can you utilize the role of

NOTE Confidence: 0.9349497

00:27:10.232 --> 00:27:12.164 circulating tumor DNA and take some

NOTE Confidence: 0.9349497

00:27:12.164 --> 00:27:14.771 of this new science so they're using

NOTE Confidence: 0.9349497

00:27:14.771 --> 00:27:17.052 the Guardian platform and apply it?

NOTE Confidence: 0.9349497

00:27:17.052 --> 00:27:20.490 And so this is being led by Van Morris,

NOTE Confidence: 0.9349497

00:27:20.490 --> 00:27:22.116 who I mentioned to you earlier

NOTE Confidence: 0.9349497

00:27:22.116 --> 00:27:23.880 is running the be raft trial,

NOTE Confidence: 0.9349497

00:27:23.880 --> 00:27:25.728 looking at patients that are either

NOTE Confidence: 0.9349497

00:27:25.728 --> 00:27:27.970 just going to receive standard

NOTE Confidence: 0.9349497

00:27:27.970 --> 00:27:29.490 care with active surveillance.

NOTE Confidence: 0.9349497

00:27:29.490 --> 00:27:32.458 Or they have their circulating tumor DNA if

NOTE Confidence: 0.9349497

00:27:32.458 --> 00:27:35.408 there's no circulating tumor DNA detected,

NOTE Confidence: 0.9349497

00:27:35.410 --> 00:27:37.528 they just go on standard surveillance.

NOTE Confidence: 0.9349497

00:27:37.530 --> 00:27:38.830 If it is positive,

NOTE Confidence: 0.9349497

00:27:38.830 --> 00:27:41.145 then they will receive full Fox Orc

NOTE Confidence: 0.9349497

00:27:41.145 --> 00:27:43.245 pox and so this trial is ongoing.

NOTE Confidence: 0.9349497

00:27:43.250 --> 00:27:45.728 So if you have stage two,

NOTE Confidence: 0.9349497

00:27:45.730 --> 00:27:47.910 play patients with colon carcinoma,

NOTE Confidence: 0.9349497

00:27:47.910 --> 00:27:51.558 please consider enrolling to this trial.

NOTE Confidence: 0.9349497

00:27:51.560 --> 00:27:53.606 There's also the circulate US study,

NOTE Confidence: 0.9349497

00:27:53.610 --> 00:27:55.136 which will be led by Chris Lu

NOTE Confidence: 0.9349497

00:27:55.136 --> 00:27:55.790 and Arvind Dasari.

NOTE Confidence: 0.9349497

00:27:55.790 --> 00:27:56.338 Once again,

NOTE Confidence: 0.9349497

00:27:56.338 --> 00:27:57.982 my very close colleagues and I've

NOTE Confidence: 0.9349497

00:27:57.982 --> 00:28:00.066 had the pleasure of working with them

NOTE Confidence: 0.9349497

00:28:00.066 --> 00:28:01.910 and mentoring them over the years.

NOTE Confidence: 0.9349497

00:28:01.910 --> 00:28:05.158 And and now they have their own trial

NOTE Confidence: 0.9349497

00:28:05.158 --> 00:28:07.622 as well. For stage three patients.

NOTE Confidence: 0.9349497

00:28:07.622 --> 00:28:09.356 And here if you're circulating

NOTE Confidence: 0.9349497

00:28:09.356 --> 00:28:10.564 tumor DNA is detected,

NOTE Confidence: 0.9349497

00:28:10.570 --> 00:28:13.036 you would be randomized to folfox

NOTE Confidence: 0.9349497

00:28:13.036 --> 00:28:15.810 Erie versus standard capox or folfox.

NOTE Confidence: 0.9349497

00:28:15.810 --> 00:28:17.818 So this trial should open up any day.

NOTE Confidence: 0.9349497

00:28:17.820 --> 00:28:19.596 It's had an amendment even before

NOTE Confidence: 0.9349497

00:28:19.596 --> 00:28:20.484 it was opened,

NOTE Confidence: 0.9349497

00:28:20.490 --> 00:28:22.016 and that's resulted in a delay in.

NOTE Confidence: 0.9349497

00:28:22.020 --> 00:28:22.659 About a year.

00:28:25.450 --> 00:28:27.222 And other ongoing trial.

00:28:27.222 --> 00:28:30.230 So in Full disclosure I am the

00:28:30.230 --> 00:28:31.854 one of the national pies here in

00:28:31.854 --> 00:28:33.110 the United States. For fresco.

00:28:33.110 --> 00:28:35.785 2 I just wanted to make sure to keep

00:28:35.785 --> 00:28:38.340 this on your radar because this trial

00:28:38.340 --> 00:28:40.373 has completed enrollment and well,

00:28:40.373 --> 00:28:41.988 hopefully we'll get some information

00:28:41.988 --> 00:28:44.108 regarding the results at some point soon,

00:28:44.110 --> 00:28:45.562 so we can determine if there

00:28:45.562 --> 00:28:47.170 is a benefit from this agent.

00:28:47.170 --> 00:28:50.512 This is an anti veg F agent as well and

00:28:50.512 --> 00:28:53.195 it was compared to placebo in patients

00:28:53.195 --> 00:28:55.818 that have been previously treated with.

00:28:55.818 --> 00:28:57.099 All standard chemotherapy,

00:28:57.100 --> 00:28:58.820 and they may have received

NOTE Confidence: 0.881475446363636

00:28:58.820 --> 00:29:00.196 regorafenib or lawn service,

NOTE Confidence: 0.881475446363636

00:29:00.200 --> 00:29:01.175 or the combination.

NOTE Confidence: 0.881475446363636

00:29:01.175 --> 00:29:01.500 Sorry,

NOTE Confidence: 0.881475446363636

00:29:01.500 --> 00:29:04.239 but exposed to both of them in the past,

NOTE Confidence: 0.881475446363636

00:29:04.240 --> 00:29:07.472 so it allowed all patients to participate in

NOTE Confidence: 0.881475446363636

00:29:07.472 --> 00:29:10.855 the reason I also wanted to demonstrate this.

NOTE Confidence: 0.881475446363636

00:29:10.860 --> 00:29:13.590 Show this to you is because in enrolled very

NOTE Confidence: 0.881475446363636

00:29:13.590 --> 00:29:16.180 quickly earlier than the expected time frame,

NOTE Confidence: 0.881475446363636

00:29:16.180 --> 00:29:19.156 and that's because it was such an unmet

NOTE Confidence: 0.881475446363636

00:29:19.156 --> 00:29:22.148 need for our pretreated metastatic

NOTE Confidence: 0.881475446363636

00:29:22.148 --> 00:29:24.317 colorectal carcinoma patients.

NOTE Confidence: 0.881475446363636

00:29:24.320 --> 00:29:26.040 There is only one phase,

NOTE Confidence: 0.881475446363636

00:29:26.040 --> 00:29:28.440 three ongoing trial at this time,

NOTE Confidence: 0.881475446363636

00:29:28.440 --> 00:29:29.920 which is an international trial.

NOTE Confidence: 0.881475446363636

00:29:29.920 --> 00:29:30.652 It's leap.

NOTE Confidence: 0.881475446363636

00:29:30.652 --> 00:29:32.848 It's based upon this very small

NOTE Confidence: 0.881475446363636

00:29:32.848 --> 00:29:35.310 study of originally 30 patients.

NOTE Confidence: 0.881475446363636

00:29:35.310 --> 00:29:37.534 They have this small phase two study of

NOTE Confidence: 0.881475446363636

00:29:37.534 --> 00:29:39.680 30 patients and they've now expanded it.

NOTE Confidence: 0.881475446363636

00:29:39.680 --> 00:29:41.152 Based upon these results.

NOTE Confidence: 0.881475446363636

00:29:41.152 --> 00:29:42.992 As you can see here,

NOTE Confidence: 0.881475446363636

00:29:43.000 --> 00:29:46.413 basically 22% with a short PFS of 2.3

NOTE Confidence: 0.881475446363636

00:29:46.413 --> 00:29:48.531 months and they've created this phase

NOTE Confidence: 0.881475446363636

00:29:48.531 --> 00:29:50.750 three trial that is ongoing looking

NOTE Confidence: 0.881475446363636

00:29:50.750 --> 00:29:53.690 at live at net plus pembrolizumab.

NOTE Confidence: 0.881475446363636

00:29:53.690 --> 00:29:56.318 So I'm trying to identify another

NOTE Confidence: 0.881475446363636

00:29:56.318 --> 00:29:58.960 potential option for patients and then

NOTE Confidence: 0.881475446363636

00:29:58.960 --> 00:30:01.265 then patients will be considered compared.

NOTE Confidence: 0.881475446363636

00:30:01.265 --> 00:30:02.855 Sorry to the standard of care

NOTE Confidence: 0.881475446363636

00:30:02.855 --> 00:30:04.310 of regorafenib or lawn service,

NOTE Confidence: 0.881475446363636

00:30:04.310 --> 00:30:06.194 so this is the only ongoing

NOTE Confidence: 0.881475446363636

00:30:06.194 --> 00:30:07.136 phase three trial.

NOTE Confidence: 0.881475446363636

00:30:07.140 --> 00:30:09.228 Currently enrolling and I'm sure it

NOTE Confidence: 0.881475446363636

00:30:09.228 --> 00:30:11.433 will also finish enrolling quickly.

NOTE Confidence: 0.881475446363636

00:30:11.433 --> 00:30:14.298 Hope I believe there's and hopefully

NOTE Confidence: 0.881475446363636

00:30:14.298 --> 00:30:16.088 another couple of other trials

NOTE Confidence: 0.881475446363636

00:30:16.088 --> 00:30:18.740 that are going to be open soon,

NOTE Confidence: 0.881475446363636

00:30:18.740 --> 00:30:20.930 but currently when I last checked,

NOTE Confidence: 0.881475446363636

00:30:20.930 --> 00:30:23.936 these were the only activated trials.

NOTE Confidence: 0.881475446363636

00:30:23.940 --> 00:30:26.860 And I wanted to touch on rectal cancer,

NOTE Confidence: 0.881475446363636

00:30:26.860 --> 00:30:28.820 'cause I think it's really important for

NOTE Confidence: 0.881475446363636

00:30:28.820 --> 00:30:30.959 people to see where the field is going

NOTE Confidence: 0.881475446363636

00:30:30.960 --> 00:30:34.900 and so traditionally for rectal cancer,

NOTE Confidence: 0.881475446363636

00:30:34.900 --> 00:30:37.110 we had always provided neoadjuvant

NOTE Confidence: 0.881475446363636

00:30:37.110 --> 00:30:38.436 chemotherapy with five,

NOTE Confidence: 0.881475446363636

00:30:38.440 --> 00:30:40.024 a few based treatment,

NOTE Confidence: 0.881475446363636

00:30:40.024 --> 00:30:42.004 and then proceeded to surgical

NOTE Confidence: 0.881475446363636

00:30:42.004 --> 00:30:44.432 resection with the Tammy and then

NOTE Confidence: 0.881475446363636

00:30:44.432 --> 00:30:46.000 followed by Advent chemotherapy.

NOTE Confidence: 0.881475446363636

00:30:46.000 --> 00:30:46.996 Whether it's five,

NOTE Confidence: 0.881475446363636

00:30:46.996 --> 00:30:48.988 a few based or oxaliplatin based,

NOTE Confidence: 0.881475446363636

00:30:48.990 --> 00:30:52.344 but the reality was that a fair number

NOTE Confidence: 0.881475446363636

00:30:52.344 --> 00:30:54.254 of patients were never receiving.

NOTE Confidence: 0.881475446363636

00:30:54.260 --> 00:30:55.787 Our Advent chemotherapy,

NOTE Confidence: 0.881475446363636

00:30:55.787 --> 00:30:58.841 either due to delays from surgical

NOTE Confidence: 0.881475446363636

00:30:58.841 --> 00:31:01.370 resection due to toxicities or wound

NOTE Confidence: 0.881475446363636

00:31:01.370 --> 00:31:04.590 healing issues or just lack of compliance

NOTE Confidence: 0.881475446363636

00:31:04.590 --> 00:31:07.659 in regards to their actual treatment.

NOTE Confidence: 0.881475446363636

00:31:07.660 --> 00:31:09.540 So what can we do to change this

NOTE Confidence: 0.881475446363636

00:31:09.540 --> 00:31:11.274 aspect and in Europe they just

NOTE Confidence: 0.881475446363636

00:31:11.274 --> 00:31:12.779 started looking at the sequence

NOTE Confidence: 0.881475446363636

00:31:12.779 --> 00:31:14.556 and then in the United States.

NOTE Confidence: 0.881475446363636

00:31:14.560 --> 00:31:16.716 We have followed suit and now it's

NOTE Confidence: 0.881475446363636

00:31:16.716 --> 00:31:18.120 called total neoadjuvant therapy.

NOTE Confidence: 0.881475446363636

00:31:18.120 --> 00:31:19.548 If you could potentially

NOTE Confidence: 0.881475446363636

00:31:19.548 --> 00:31:20.976 provide all your treatment,

NOTE Confidence: 0.881475446363636

00:31:20.980 --> 00:31:22.630 chemotherapy and your

NOTE Confidence: 0.881475446363636

00:31:22.630 --> 00:31:24.280 chemo radiation therapy.

NOTE Confidence: 0.881475446363636

00:31:24.280 --> 00:31:26.420 Up front before consideration of

NOTE Confidence: 0.881475446363636

00:31:26.420 --> 00:31:28.560 surgical resection or the reverse

NOTE Confidence: 0.881475446363636

00:31:28.630 --> 00:31:31.045 sequence where it chemo radiation

NOTE Confidence: 0.881475446363636

00:31:31.045 --> 00:31:32.977 therapy followed by chemotherapy,

NOTE Confidence: 0.881475446363636

00:31:32.980 --> 00:31:34.780 but I wanted to touch upon

NOTE Confidence: 0.881475446363636

00:31:34.780 --> 00:31:35.980 this trial because it's

NOTE Confidence: 0.898623703636364

00:31:36.045 --> 00:31:38.349 important that I do want to mention this

NOTE Confidence: 0.898623703636364

00:31:38.349 --> 00:31:41.285 and the other reason is that obviously,

NOTE Confidence: 0.898623703636364

00:31:41.285 --> 00:31:43.333 radiation therapy has known

NOTE Confidence: 0.898623703636364

00:31:43.333 --> 00:31:45.698 toxicities and for our patients.

NOTE Confidence: 0.898623703636364

00:31:45.700 --> 00:31:46.864 This is obviously an issue that

NOTE Confidence: 0.898623703636364

00:31:46.864 --> 00:31:48.458 we do want to take into account,

NOTE Confidence: 0.898623703636364

00:31:48.460 --> 00:31:51.076 so is there a way to reduce our

NOTE Confidence: 0.898623703636364

00:31:51.076 --> 00:31:53.942 toxicities and is there a way potentially

NOTE Confidence: 0.898623703636364

00:31:53.942 --> 00:31:56.077 to even avoid surgical resection?

NOTE Confidence: 0.898623703636364

00:31:56.080 --> 00:31:58.960 So this is Angelita Habr Gama,

NOTE Confidence: 0.898623703636364

00:31:58.960 --> 00:32:00.962 who at leave is in her late

NOTE Confidence: 0.898623703636364

00:32:00.962 --> 00:32:03.194 80s at at this point,

NOTE Confidence: 0.898623703636364

00:32:03.194 --> 00:32:05.844 and when she originally published

NOTE Confidence: 0.898623703636364

00:32:05.844 --> 00:32:09.228 on the consideration of just

NOTE Confidence: 0.898623703636364

00:32:09.228 --> 00:32:11.500 observing by close surveillance,

NOTE Confidence: 0.898623703636364

00:32:11.500 --> 00:32:14.332 those patients that had had a

NOTE Confidence: 0.898623703636364

00:32:14.332 --> 00:32:17.020 significant response to their treatment

NOTE Confidence: 0.898623703636364

00:32:17.020 --> 00:32:19.440 instead of proceeding with TMA,

NOTE Confidence: 0.898623703636364

00:32:19.440 --> 00:32:21.440 can you watch and wait?

NOTE Confidence: 0.898623703636364

00:32:21.440 --> 00:32:23.155 Basically do a watch and wait approach

NOTE Confidence: 0.898623703636364

00:32:23.155 --> 00:32:24.914 and watch them conservatively and when

NOTE Confidence: 0.898623703636364

00:32:24.914 --> 00:32:26.858 she originally brought up this concept?

NOTE Confidence: 0.898623703636364

00:32:26.860 --> 00:32:28.380 She herself as a surgeon.

NOTE Confidence: 0.898623703636364

00:32:28.380 --> 00:32:30.020 People thought there was this

NOTE Confidence: 0.898623703636364

00:32:30.020 --> 00:32:32.310 was this could not be possible.

NOTE Confidence: 0.898623703636364

00:32:32.310 --> 00:32:34.770 This data was not real.

NOTE Confidence: 0.898623703636364

00:32:34.770 --> 00:32:37.946 Why would a surgeon not offer a patient

NOTE Confidence: 0.898623703636364

00:32:37.946 --> 00:32:40.119 surgical resection with rectal cancer?

NOTE Confidence: 0.898623703636364

00:32:40.120 --> 00:32:42.604 And in fact, she appears to have caught up.

NOTE Confidence: 0.898623703636364

00:32:42.610 --> 00:32:44.584 Obviously she was way ahead of her

NOTE Confidence: 0.898623703636364

00:32:44.584 --> 00:32:47.418 time once again for this amazing idea.

NOTE Confidence: 0.898623703636364

00:32:47.418 --> 00:32:51.022 So now we have some very interesting data

NOTE Confidence: 0.898623703636364

00:32:51.022 --> 00:32:53.440 from the Memorial Sloan Kettering Group.

NOTE Confidence: 0.898623703636364

00:32:53.440 --> 00:32:55.660 They created the Oprah trial,

NOTE Confidence: 0.898623703636364

00:32:55.660 --> 00:32:58.296 the Oprah trial was a. Phase two study.

NOTE Confidence: 0.898623703636364

00:32:58.296 --> 00:33:00.256 I don't want to emphasize.

NOTE Confidence: 0.898623703636364

00:33:00.260 --> 00:33:01.500 This needs to be validated.

NOTE Confidence: 0.898623703636364

00:33:01.500 --> 00:33:03.922 This is a phase two study done

NOTE Confidence: 0.898623703636364

00:33:03.922 --> 00:33:06.169 that was completed at select sites.

NOTE Confidence: 0.898623703636364

00:33:06.170 --> 00:33:08.592 I think about 15 to 18 sites

NOTE Confidence: 0.898623703636364

00:33:08.592 --> 00:33:10.900 in low lying rectal tumors.

NOTE Confidence: 0.898623703636364

00:33:10.900 --> 00:33:13.965 Providing the patients either chemo

NOTE Confidence: 0.898623703636364

00:33:13.965 --> 00:33:17.030 radiation therapy followed by chemotherapy

NOTE Confidence: 0.898623703636364

00:33:17.113 --> 00:33:18.857 or induction chemotherapy followed

NOTE Confidence: 0.898623703636364

00:33:18.857 --> 00:33:21.502 by chemoradiation therapy and the

NOTE Confidence: 0.898623703636364

00:33:21.502 --> 00:33:25.192 patients were evaluated by endoscopy and MRI.

NOTE Confidence: 0.898623703636364

00:33:25.192 --> 00:33:28.120 If they had no complete response.

NOTE Confidence: 0.898623703636364

00:33:28.120 --> 00:33:30.562 Then they went on to total

NOTE Confidence: 0.898623703636364

00:33:30.562 --> 00:33:32.020 misso rectal excision,

NOTE Confidence: 0.898623703636364

00:33:32.020 --> 00:33:34.645 or they had clinical response.

NOTE Confidence: 0.898623703636364

00:33:34.650 --> 00:33:38.500 You could undergo watch and wait approach.

NOTE Confidence: 0.898623703636364

00:33:38.500 --> 00:33:40.789 And here you can see regardless of

NOTE Confidence: 0.898623703636364

00:33:40.789 --> 00:33:42.659 the sequence that you received,

NOTE Confidence: 0.898623703636364

00:33:42.660 --> 00:33:46.290 there was equivalent disease free survival.

NOTE Confidence: 0.898623703636364

00:33:46.290 --> 00:33:49.349 But he also noted, was those patients

NOTE Confidence: 0.898623703636364

00:33:49.349 --> 00:33:51.839 once again low lying tumors.

NOTE Confidence: 0.898623703636364

00:33:51.840 --> 00:33:53.856 Stage tumors stage three.

NOTE Confidence: 0.898623703636364

00:33:53.856 --> 00:33:56.376 If you received chemo radiation

NOTE Confidence: 0.898623703636364

00:33:56.376 --> 00:33:59.167 therapy first then followed by

NOTE Confidence: 0.898623703636364

00:33:59.167 --> 00:34:01.375 chemotherapy for systemic therapy,

NOTE Confidence: 0.898623703636364

00:34:01.380 --> 00:34:03.336 these patients appear to be more

NOTE Confidence: 0.898623703636364

00:34:03.336 --> 00:34:05.026 likely to have sphincter preservation

NOTE Confidence: 0.898623703636364

00:34:05.026 --> 00:34:07.273 and were more likely to undergo a

NOTE Confidence: 0.898623703636364

00:34:07.273 --> 00:34:09.047 watch and wait approach because

NOTE Confidence: 0.898623703636364

00:34:09.047 --> 00:34:10.837 of their degree of response.

NOTE Confidence: 0.898623703636364

00:34:10.840 --> 00:34:12.770 Now this is phase two.

NOTE Confidence: 0.898623703636364

00:34:12.770 --> 00:34:13.688 It is being.

NOTE Confidence: 0.864575737142857

00:34:16.290 --> 00:34:19.517 Expanded more, not the exact same way,

NOTE Confidence: 0.864575737142857

00:34:19.520 --> 00:34:21.704 but it is going to be a phase

NOTE Confidence: 0.864575737142857

00:34:21.704 --> 00:34:23.520 three trial led by Josh Smith.

NOTE Confidence: 0.864575737142857

00:34:23.520 --> 00:34:25.340 Also for Morris Sloan Kettering.

NOTE Confidence: 0.864575737142857

00:34:25.340 --> 00:34:28.000 For consideration of this watch

NOTE Confidence: 0.864575737142857

00:34:28.000 --> 00:34:30.971 and wait approach and once again

NOTE Confidence: 0.864575737142857

00:34:30.971 --> 00:34:33.713 we need to validate the data.

NOTE Confidence: 0.864575737142857

00:34:33.720 --> 00:34:35.380 Now they did update their

NOTE Confidence: 0.864575737142857

00:34:35.380 --> 00:34:37.550 data just so you are aware.

NOTE Confidence: 0.864575737142857

00:34:37.550 --> 00:34:39.920 At last year's ASCO and here's

NOTE Confidence: 0.864575737142857

00:34:39.920 --> 00:34:41.500 pictures of clinical complete

NOTE Confidence: 0.864575737142857

00:34:41.566 --> 00:34:44.196 response near complete response and

NOTE Confidence: 0.864575737142857

00:34:44.196 --> 00:34:46.270 incomplete complete response and the

NOTE Confidence: 0.864575737142857

00:34:46.270 --> 00:34:47.740 time frame of which they assessed.

NOTE Confidence: 0.864575737142857

00:34:47.740 --> 00:34:48.613 When the response.

NOTE Confidence: 0.864575737142857

00:34:48.613 --> 00:34:50.359 Sorry of the degree of response,

NOTE Confidence: 0.864575737142857

00:34:50.360 --> 00:34:53.408 was roughly 7 to 8 weeks.

NOTE Confidence: 0.864575737142857

00:34:53.410 --> 00:34:55.450 And here you can see when

NOTE Confidence: 0.864575737142857

00:34:55.450 --> 00:34:56.810 looking at organ preservation,

NOTE Confidence: 0.864575737142857

00:34:56.810 --> 00:34:58.970 obviously those that had a political

NOTE Confidence: 0.864575737142857

00:34:58.970 --> 00:35:00.736 complete response at three years

NOTE Confidence: 0.864575737142857

00:35:00.736 --> 00:35:03.775 that was 78% versus a near complete

NOTE Confidence: 0.864575737142857

00:35:03.775 --> 00:35:06.680 response at three years was 45%.

NOTE Confidence: 0.864575737142857

00:35:06.680 --> 00:35:09.798 So obviously there was possible there's

NOTE Confidence: 0.864575737142857

00:35:09.798 --> 00:35:12.102 possibility of a watch and wait

NOTE Confidence: 0.864575737142857

00:35:12.102 --> 00:35:14.330 approach for some of your patients.

NOTE Confidence: 0.864575737142857

00:35:14.330 --> 00:35:15.930 Whenever we have this opportunity,

NOTE Confidence: 0.864575737142857

00:35:15.930 --> 00:35:18.180 we review it with both our

NOTE Confidence: 0.864575737142857

00:35:18.180 --> 00:35:18.930 radiation oncologists,

NOTE Confidence: 0.864575737142857

00:35:18.930 --> 00:35:20.430 our surgical oncologists and our

NOTE Confidence: 0.864575737142857

00:35:20.430 --> 00:35:21.930 medical oncologists and really make

NOTE Confidence: 0.864575737142857

00:35:21.978 --> 00:35:23.478 this a multidisciplinary approach.

NOTE Confidence: 0.864575737142857

00:35:23.480 --> 00:35:25.255 Then discuss it at our

NOTE Confidence: 0.864575737142857

00:35:25.255 --> 00:35:26.320 multidisciplinary tumor board,

NOTE Confidence: 0.864575737142857

00:35:26.320 --> 00:35:27.440 and I obviously encourage

NOTE Confidence: 0.864575737142857

00:35:27.440 --> 00:35:29.120 everyone else to do the same.

NOTE Confidence: 0.864575737142857

00:35:29.120 --> 00:35:30.008 So very intriguing.

NOTE Confidence: 0.864575737142857

00:35:30.008 --> 00:35:31.192 Obviously we look forward

NOTE Confidence: 0.864575737142857

00:35:31.192 --> 00:35:32.750 to the phase three trial.

NOTE Confidence: 0.925890016

00:35:34.850 --> 00:35:36.500 And last but not least,

NOTE Confidence: 0.925890016

00:35:36.500 --> 00:35:38.572 I do want to touch pad on something

NOTE Confidence: 0.925890016

00:35:38.572 --> 00:35:40.872 very dear to me or early onset

NOTE Confidence: 0.925890016

00:35:40.872 --> 00:35:41.907 colorectal cancer patients,

NOTE Confidence: 0.925890016

00:35:41.910 --> 00:35:44.409 so this data is not new data.

NOTE Confidence: 0.925890016

00:35:44.410 --> 00:35:46.522 This is looking at the senior

NOTE Confidence: 0.925890016

00:35:46.522 --> 00:35:48.082 database from 1975 to 2010.

NOTE Confidence: 0.925890016

00:35:48.082 --> 00:35:49.502 It was originally published by

NOTE Confidence: 0.925890016

00:35:49.502 --> 00:35:50.919 Christina Bailey, who is actually

NOTE Confidence: 0.925890016

00:35:50.919 --> 00:35:52.617 now my colleague here at Vanderbilt.

NOTE Confidence: 0.925890016

00:35:52.620 --> 00:35:53.952 She wrote this when she was

NOTE Confidence: 0.925890016

00:35:53.952 --> 00:35:55.370 a fellow at MD Anderson,

NOTE Confidence: 0.925890016

00:35:55.370 --> 00:35:56.636 and as you can see here.

NOTE Confidence: 0.950167764

00:35:58.790 --> 00:36:01.819 As you can see here, there is an

NOTE Confidence: 0.950167764

00:36:01.819 --> 00:36:03.937 expected increase over the next decade

NOTE Confidence: 0.950167764

00:36:03.937 --> 00:36:06.188 for our young patients in Blues,

NOTE Confidence: 0.950167764

00:36:06.190 --> 00:36:08.157 20 to 34 years of age and

NOTE Confidence: 0.950167764

00:36:08.157 --> 00:36:10.608 red is 35 to 49 years of age.

NOTE Confidence: 0.950167764

00:36:10.610 --> 00:36:12.864 I'm sorry somebody has the wrong number.

NOTE Confidence: 0.950167764

00:36:12.870 --> 00:36:15.954 I apologize and rectal cancer also

NOTE Confidence: 0.950167764

00:36:15.954 --> 00:36:19.552 is supposed to be increased by the

NOTE Confidence: 0.950167764

00:36:19.552 --> 00:36:22.350 year 2030 by 124% in the very young.

NOTE Confidence: 0.950167764

00:36:22.350 --> 00:36:24.618 The 20 to 34 year age group.

NOTE Confidence: 0.933971012857143

00:36:26.770 --> 00:36:28.538 This obviously was recognized

NOTE Confidence: 0.933971012857143

00:36:28.538 --> 00:36:29.864 by patient advocates,

NOTE Confidence: 0.933971012857143

00:36:29.870 --> 00:36:32.246 patients and their providers as well,

NOTE Confidence: 0.933971012857143

00:36:32.250 --> 00:36:34.385 and this resulted in a change and

NOTE Confidence: 0.933971012857143

00:36:34.385 --> 00:36:37.169 I think as many of you are aware

NOTE Confidence: 0.933971012857143

00:36:37.169 --> 00:36:38.969 by the US preventive taskforce

NOTE Confidence: 0.933971012857143

00:36:39.043 --> 00:36:41.035 to reduce our screening age from

NOTE Confidence: 0.933971012857143

00:36:41.035 --> 00:36:43.216 50 years old to 45 years old,

NOTE Confidence: 0.933971012857143

00:36:43.216 --> 00:36:45.190 and so this is a new recommendation.

NOTE Confidence: 0.933971012857143

00:36:45.190 --> 00:36:47.479 Obviously if the patient is having symptoms

NOTE Confidence: 0.933971012857143

00:36:47.479 --> 00:36:49.668 and it's younger than 45 years of age,

NOTE Confidence: 0.933971012857143

00:36:49.670 --> 00:36:54.260 we would encourage screening immediately.

NOTE Confidence: 0.933971012857143

00:36:54.260 --> 00:36:56.798 But this is an issue you can see here.

NOTE Confidence: 0.933971012857143

00:36:56.800 --> 00:36:59.316 Trends in the United States looking at 2001

NOTE Confidence: 0.933971012857143

00:36:59.316 --> 00:37:02.298 through 2005 versus a decade later on.

NOTE Confidence: 0.933971012857143

00:37:02.300 --> 00:37:04.204 And you can see there's an increased

NOTE Confidence: 0.933971012857143

00:37:04.204 --> 00:37:06.260 incidence of young onset colorectal cancer,

NOTE Confidence: 0.933971012857143

00:37:06.260 --> 00:37:08.050 and especially in those states

NOTE Confidence: 0.933971012857143

00:37:08.050 --> 00:37:12.118 with higher incidence of obesity.

NOTE Confidence: 0.933971012857143

00:37:12.120 --> 00:37:13.515 This actually has been demonstrated

NOTE Confidence: 0.933971012857143

00:37:13.515 --> 00:37:15.599 as well in the nurses health study.

NOTE Confidence: 0.933971012857143

00:37:15.600 --> 00:37:18.210 Looking at your current BMI and

NOTE Confidence: 0.933971012857143

00:37:18.210 --> 00:37:20.590 your risk of colorectal cancer.

NOTE Confidence: 0.933971012857143

00:37:20.590 --> 00:37:22.300 And there's also been some interesting

NOTE Confidence: 0.933971012857143

00:37:22.300 --> 00:37:23.987 data looking at the role of

NOTE Confidence: 0.933971012857143

00:37:23.987 --> 00:37:25.463 antibiotic use and exposure and how

NOTE Confidence: 0.933971012857143

00:37:25.463 --> 00:37:27.090 it may impact the microbiome.

NOTE Confidence: 0.933971012857143

00:37:27.090 --> 00:37:29.601 This is one of roughly about three to four

NOTE Confidence: 0.933971012857143

00:37:29.601 --> 00:37:31.948 studies that have been published as of late.

NOTE Confidence: 0.933971012857143

00:37:31.950 --> 00:37:33.258 So intriguing data.

NOTE Confidence: 0.933971012857143

00:37:33.258 --> 00:37:34.130 Once again,

NOTE Confidence: 0.933971012857143

00:37:34.130 --> 00:37:35.780 we don't know the exact

NOTE Confidence: 0.933971012857143

00:37:35.780 --> 00:37:37.430 reason why our young adults,

NOTE Confidence: 0.933971012857143

00:37:37.430 --> 00:37:38.850 who the majority of them,

NOTE Confidence: 0.933971012857143

00:37:38.850 --> 00:37:40.650 have spontaneous colorectal cancer.

NOTE Confidence: 0.933971012857143

00:37:40.650 --> 00:37:44.217 They do not have Lynch syndrome or developing

NOTE Confidence: 0.933971012857143

00:37:44.217 --> 00:37:46.989 colorectal cancer at such an early age.

NOTE Confidence: 0.933971012857143

00:37:46.990 --> 00:37:50.438 So we had the honor of publishing a

NOTE Confidence: 0.933971012857143

00:37:50.438 --> 00:37:53.242 picture paper recently in Lansing

NOTE Confidence: 0.933971012857143

00:37:53.242 --> 00:37:55.255 Oncology looking at how to create

NOTE Confidence: 0.933971012857143

00:37:55.255 --> 00:37:56.650 a framework for these patients.

NOTE Confidence: 0.933971012857143

00:37:56.650 --> 00:37:57.330 As many of you know,

NOTE Confidence: 0.933971012857143

00:37:57.330 --> 00:37:59.676 I'm I've created this young Adult

NOTE Confidence: 0.933971012857143

00:37:59.676 --> 00:38:01.863 Cancer Center here at our institution,

NOTE Confidence: 0.933971012857143

67

00:38:01.863 --> 00:38:03.861 which is not just for colorectal

NOTE Confidence: 0.933971012857143

00:38:03.861 --> 00:38:04.527 cancer patients.

NOTE Confidence: 0.933971012857143

00:38:04.530 --> 00:38:06.720 It's for all young adult cancer

NOTE Confidence: 0.933971012857143

00:38:06.720 --> 00:38:09.079 patients between the ages of 20 and 45,

NOTE Confidence: 0.933971012857143

00:38:09.080 --> 00:38:10.459 and these are some of the aspects

NOTE Confidence: 0.933971012857143

00:38:10.459 --> 00:38:11.833 you really need to think about

NOTE Confidence: 0.933971012857143

00:38:11.833 --> 00:38:13.063 when you're seeing these patients.

NOTE Confidence: 0.933971012857143

00:38:13.070 --> 00:38:14.786 Fertility financial guidance,

NOTE Confidence: 0.933971012857143

00:38:14.786 --> 00:38:17.074 physical wealth beating being.

NOTE Confidence: 0.933971012857143

00:38:17.080 --> 00:38:18.950 Sorry.

NOTE Confidence: 0.933971012857143

00:38:18.950 --> 00:38:22.126 But other concerns obviously

NOTE Confidence: 0.933971012857143

00:38:22.126 --> 00:38:24.596 regarding job security,

NOTE Confidence: 0.933971012857143

00:38:24.596 --> 00:38:29.058 body image and just the fear of not

NOTE Confidence: 0.933971012857143

00:38:29.058 --> 00:38:31.050 knowing exactly how best to address this,

NOTE Confidence: 0.933971012857143

00:38:31.050 --> 00:38:33.430 because these individuals are very

NOTE Confidence: 0.933971012857143

00:38:33.430 --> 00:38:35.378 young and they're going through

NOTE Confidence: 0.933971012857143

00:38:35.378 --> 00:38:37.580 a very different aspect of their

NOTE Confidence: 0.933971012857143

00:38:37.648 --> 00:38:39.622 life versus our older median age

NOTE Confidence: 0.933971012857143

00:38:39.622 --> 00:38:41.260 patient of 67 years old.

NOTE Confidence: 0.933971012857143

00:38:41.260 --> 00:38:43.580 In addition, we you know,

NOTE Confidence: 0.933971012857143

00:38:43.580 --> 00:38:44.956 as you can guess,

NOTE Confidence: 0.933971012857143

00:38:44.956 --> 00:38:46.676 these patients face other concerns,

NOTE Confidence: 0.933971012857143

00:38:46.680 --> 00:38:48.117 especially regarding financial

NOTE Confidence: 0.933971012857143

00:38:48.117 --> 00:38:50.991 toxicities and and the the pressure

NOTE Confidence: 0.933971012857143

00:38:50.991 --> 00:38:54.058 that they feel because some of them

NOTE Confidence: 0.933971012857143

00:38:54.058 --> 00:38:56.338 obviously are still working and

NOTE Confidence: 0.933971012857143

00:38:56.338 --> 00:38:59.239 don't have financial independency.

NOTE Confidence: 0.933971012857143

00:38:59.240 --> 00:39:00.556 They're not financially independent,

NOTE Confidence: 0.933971012857143

00:39:00.556 --> 00:39:02.530 but they don't have to worry

NOTE Confidence: 0.933971012857143

00:39:02.584 --> 00:39:03.749 about the cost of care,

NOTE Confidence: 0.933971012857143

00:39:03.750 --> 00:39:05.646 and so these are important things

NOTE Confidence: 0.933971012857143

69

00:39:05.646 --> 00:39:07.728 to take into account for our

NOTE Confidence: 0.933971012857143

00:39:07.728 --> 00:39:09.248 young adult patient population.

NOTE Confidence: 0.933971012857143

00:39:09.250 --> 00:39:10.606 So here are my Co directors.

NOTE Confidence: 0.933971012857143

00:39:10.610 --> 00:39:12.326 I just wanted to highlight that

NOTE Confidence: 0.933971012857143

00:39:12.326 --> 00:39:14.036 Michael Byrne and Libby Davis.

NOTE Confidence: 0.933971012857143

00:39:14.036 --> 00:39:15.728 Michael Byrne is BMT,

NOTE Confidence: 0.933971012857143

00:39:15.730 --> 00:39:18.450 and Libby Davis in sarcoma.

NOTE Confidence: 0.933971012857143

00:39:18.450 --> 00:39:20.396 And this is just the information on

NOTE Confidence: 0.933971012857143

00:39:20.396 --> 00:39:22.461 our program and we're very grateful to

NOTE Confidence: 0.933971012857143

00:39:22.461 --> 00:39:24.638 have many involved in our group and

NOTE Confidence: 0.933971012857143

00:39:24.638 --> 00:39:26.408 provide resources for our patients.

NOTE Confidence: 0.933971012857143

00:39:26.410 --> 00:39:29.394 And this was actually one of my patients.

NOTE Confidence: 0.933971012857143

00:39:29.400 --> 00:39:32.049 She was 32.

NOTE Confidence: 0.933971012857143

00:39:32.050 --> 00:39:32.455 And you know,

NOTE Confidence: 0.933971012857143

00:39:32.455 --> 00:39:33.265 I love it when people say,

NOTE Confidence: 0.960773912

00:39:33.270 --> 00:39:34.370 well, you look too healthy.

00:39:34.370 --> 00:39:35.870 You can't have colorectal cancer.

00:39:35.870 --> 00:39:38.114 Well, she was training for a

00:39:38.114 --> 00:39:40.190 marathon and she was in great

00:39:40.190 --> 00:39:41.890 health but had bowel issues,

00:39:41.890 --> 00:39:43.760 probably for about 8 months.

00:39:43.760 --> 00:39:45.795 They kept in telling her

00:39:45.795 --> 00:39:47.864 that she had irritable bowel

00:39:47.864 --> 00:39:49.974 disease or it was hemorrhoids,

00:39:49.980 --> 00:39:53.136 or it's from her marathon training.

00:39:53.140 --> 00:39:56.440 And when I saw her she had about 50 to

00:39:56.529 --> 00:39:58.608 60% of her liver involved with tumor.

00:39:58.610 --> 00:40:02.110 Unfortunately, she as you can see here.

00:40:02.110 --> 00:40:05.040 She fought for with her basically

00:40:05.040 --> 00:40:08.480 was amazing individual thought

00:40:08.480 --> 00:40:11.060 her colorectal cancer.

00:40:11.060 --> 00:40:13.951 Lived with it for about five years

NOTE Confidence: 0.960773912

00:40:13.951 --> 00:40:15.540 and unfortunately passed away

NOTE Confidence: 0.960773912

00:40:15.540 --> 00:40:17.208 the latter part of last year,

NOTE Confidence: 0.960773912

00:40:17.210 --> 00:40:19.058 but during her time she made a

NOTE Confidence: 0.960773912

00:40:19.058 --> 00:40:21.024 huge effort to serve an advocacy

NOTE Confidence: 0.960773912

00:40:21.024 --> 00:40:23.244 groups and became a national patient

NOTE Confidence: 0.960773912

00:40:23.244 --> 00:40:25.107 advocate for the fight colorectal

NOTE Confidence: 0.960773912

00:40:25.107 --> 00:40:27.255 cancer program and that was actually

NOTE Confidence: 0.960773912

00:40:27.260 --> 00:40:30.132 a picture of her in Times Square and

NOTE Confidence: 0.960773912

00:40:30.132 --> 00:40:33.086 she used to run regularly these 5K

NOTE Confidence: 0.960773912

00:40:33.086 --> 00:40:35.640 events with her friends walk run.

NOTE Confidence: 0.960773912

00:40:35.640 --> 00:40:37.388 So in closing points,

NOTE Confidence: 0.960773912

00:40:37.388 --> 00:40:39.136 Please remember screening starts

NOTE Confidence: 0.960773912

00:40:39.136 --> 00:40:40.800 at the age of 45.

NOTE Confidence: 0.960773912

00:40:40.800 --> 00:40:42.300 Please continue to educate others

NOTE Confidence: 0.960773912

00:40:42.300 --> 00:40:44.155 about the signs and symptoms of

NOTE Confidence: 0.960773912

00:40:44.155 --> 00:40:45.375 colorectal cancer and recognize

NOTE Confidence: 0.960773912

00:40:45.375 --> 00:40:47.422 that these patients may need to be

NOTE Confidence: 0.960773912

00:40:47.422 --> 00:40:49.081 screened earlier than 45 if they have

NOTE Confidence: 0.960773912

00:40:49.081 --> 00:40:51.100 these symptoms that do not resolve,

NOTE Confidence: 0.960773912

00:40:51.100 --> 00:40:53.512 recognize the unmet needs are so

NOTE Confidence: 0.960773912

00:40:53.512 --> 00:40:55.820 psychosocial needs of our patients.

NOTE Confidence: 0.960773912

00:40:55.820 --> 00:40:56.200 Currently,

NOTE Confidence: 0.960773912

00:40:56.200 --> 00:40:58.480 most of the advances in colorectal

NOTE Confidence: 0.960773912

00:40:58.480 --> 00:41:00.689 cancer have largely been made in

NOTE Confidence: 0.960773912

00:41:00.689 --> 00:41:02.267 the rare molecular subtypes and

NOTE Confidence: 0.960773912

00:41:02.267 --> 00:41:03.689 for the majority of our patients.

NOTE Confidence: 0.960773912

00:41:03.690 --> 00:41:05.000 We still need novel agents

NOTE Confidence: 0.960773912

00:41:05.000 --> 00:41:06.048 and unfortunately for us.

NOTE Confidence: 0.960773912

00:41:06.050 --> 00:41:08.360 Colorectal cancer IO therapy has

NOTE Confidence: 0.960773912

00:41:08.360 --> 00:41:10.208 had limited efficacy excluding

NOTE Confidence: 0.960773912

00:41:10.208 --> 00:41:12.000 in MSI high patients.

NOTE Confidence: 0.960773912

00:41:12.000 --> 00:41:13.305 Next generation sequencing is always

NOTE Confidence: 0.960773912

00:41:13.305 --> 00:41:15.210 the standard of care for our patients,

NOTE Confidence: 0.960773912

00:41:15.210 --> 00:41:15.966 and I always,

NOTE Confidence: 0.960773912

00:41:15.966 --> 00:41:16.218 always,

NOTE Confidence: 0.960773912

00:41:16.218 --> 00:41:18.488 always try to enroll to a clinical trial

NOTE Confidence: 0.960773912

00:41:18.488 --> 00:41:20.582 whenever possible so we can obviously

NOTE Confidence: 0.960773912

00:41:20.582 --> 00:41:22.359 make greater treatment advances.

NOTE Confidence: 0.960773912

00:41:22.360 --> 00:41:24.096 So thank you so much for your

NOTE Confidence: 0.960773912

00:41:24.096 --> 00:41:26.000 attention and I would be happy

NOTE Confidence: 0.960773912

00:41:26.000 --> 00:41:27.320 to take any questions.

NOTE Confidence: 0.81348383

00:41:29.720 --> 00:41:30.948 Kathy, that was great.

NOTE Confidence: 0.743005221666667

00:41:31.490 --> 00:41:32.750 I didn't talk to you fast.

NOTE Confidence: 0.620743623923077

00:41:33.140 --> 00:41:35.844 No no, no no. It was perfect and

NOTE Confidence: 0.620743623923077

00:41:35.844 --> 00:41:38.109 it was incredibly informative

NOTE Confidence: 0.620743623923077

00:41:38.109 --> 00:41:40.360 and really just wonderful.

NOTE Confidence: 0.620743623923077

00:41:40.360 --> 00:41:44.790 I think Nita may have the first question.

NOTE Confidence: 0.88955605

00:41:48.040 --> 00:41:50.410 Thank you Kathy, and thanks Eric.

NOTE Confidence: 0.85948918375

00:41:50.410 --> 00:41:52.050 I ask Doctor Wyner,

NOTE Confidence: 0.85948918375

00:41:52.050 --> 00:41:54.100 mentioned really informative and and

NOTE Confidence: 0.85948918375

00:41:54.100 --> 00:41:56.527 taking us through where the field is.

NOTE Confidence: 0.85948918375

00:41:56.530 --> 00:41:59.492 Perhaps my first question to you is

NOTE Confidence: 0.85948918375

00:41:59.492 --> 00:42:01.685 more around rectal cancer management.

NOTE Confidence: 0.85948918375

00:42:01.685 --> 00:42:03.305 And as you mentioned,

NOTE Confidence: 0.85948918375

00:42:03.310 --> 00:42:05.260 at the end of the hammer,

NOTE Confidence: 0.85948918375

00:42:05.260 --> 00:42:07.654 gamedata and watchful waiting and I

NOTE Confidence: 0.85948918375

00:42:07.654 --> 00:42:10.370 think the early trial on neoadjuvant.

NOTE Confidence: 0.85948918375

00:42:10.370 --> 00:42:12.348 I think part of the worry there is are you?

NOTE Confidence: 0.85948918375

00:42:12.350 --> 00:42:14.289 How are you all accounting in this

NOTE Confidence: 0.85948918375

00:42:14.289 --> 00:42:16.628 you know is around this field where

NOTE Confidence: 0.85948918375

00:42:16.628 --> 00:42:18.433 there's not only a biological?

NOTE Confidence: 0.85948918375

00:42:18.440 --> 00:42:19.556 Implications, but.

NOTE Confidence: 0.85948918375

00:42:19.556 --> 00:42:21.788 Quality of life implications.

NOTE Confidence: 0.85948918375

00:42:21.790 --> 00:42:25.127 That is, do you miss the window on a

NOTE Confidence: 0.85948918375

00:42:25.127 --> 00:42:26.909 curative approach without an ostomy and

NOTE Confidence: 0.85948918375

00:42:26.909 --> 00:42:29.618 and and I wonder if that was considered,

NOTE Confidence: 0.85948918375

00:42:29.620 --> 00:42:30.980 especially in that first trial,

NOTE Confidence: 0.85948918375

00:42:30.980 --> 00:42:33.540 which I thought was.

NOTE Confidence: 0.85948918375

00:42:33.540 --> 00:42:35.084 Interesting that people at

NOTE Confidence: 0.85948918375

00:42:35.084 --> 00:42:37.277 Memorial agree to do that to

NOTE Confidence: 0.85948918375

00:42:37.277 --> 00:42:38.819 put in Check Point early on.

NOTE Confidence: 0.85948918375

00:42:38.820 --> 00:42:41.106 And because you may lose a window and I

NOTE Confidence: 0.85948918375

00:42:41.106 --> 00:42:43.456 wonder where you think the field is on that.

NOTE Confidence: 0.85948918375

00:42:43.460 --> 00:42:44.839 And then I have a bigger question.

NOTE Confidence: 0.85948918375

00:42:44.840 --> 00:42:46.408 Perhaps around colon cancer,

NOTE Confidence: 0.842676015

00:42:46.840 --> 00:42:51.256 I think because number one in rectal cancer,

NOTE Confidence: 0.842676015

00:42:51.260 --> 00:42:52.996 you know as as I showed you,

NOTE Confidence: 0.842676015

00:42:53.000 --> 00:42:55.040 the incidence is expected to be

NOTE Confidence: 0.842676015

00:42:55.040 --> 00:42:57.239 quite higher over the next decade,

NOTE Confidence: 0.842676015

00:42:57.240 --> 00:42:58.960 especially for our young patients.

NOTE Confidence: 0.842676015

00:42:58.960 --> 00:43:01.558 So from my own personal experience,

NOTE Confidence: 0.842676015

00:43:01.560 --> 00:43:03.792 when I'm seeing these patients a lot of

NOTE Confidence: 0.842676015

00:43:03.792 --> 00:43:06.396 them are willing to take that risk because

NOTE Confidence: 0.842676015

00:43:06.396 --> 00:43:08.827 especially if they have a low lying tumor,

NOTE Confidence: 0.842676015

00:43:08.830 --> 00:43:12.288 they don't want to consider an APR,

NOTE Confidence: 0.842676015

00:43:12.290 --> 00:43:14.898 and so they're willing to consider that risk

NOTE Confidence: 0.842676015

00:43:14.898 --> 00:43:17.746 as long as they're being followed closely,

NOTE Confidence: 0.842676015

00:43:17.750 --> 00:43:19.507 and many of them are extremely compliant,

NOTE Confidence: 0.842676015

00:43:19.510 --> 00:43:20.722 then in that setting.

NOTE Confidence: 0.842676015

00:43:20.722 --> 00:43:22.950 So I think that in that case,

NOTE Confidence: 0.842676015

00:43:22.950 --> 00:43:25.438 as long as they have a good relationship

NOTE Confidence: 0.842676015

00:43:25.438 --> 00:43:27.700 with their surgical oncologist and

NOTE Confidence: 0.842676015

00:43:27.700 --> 00:43:29.581 medical oncologist, I think it's

NOTE Confidence: 0.842676015

00:43:29.581 --> 00:43:31.243 very reasonable to consider it in.

NOTE Confidence: 0.842676015

00:43:31.250 --> 00:43:32.440 In that setting, you know.

NOTE Confidence: 0.842676015

00:43:32.440 --> 00:43:34.160 Obviously what I didn't show you is that.

NOTE Confidence: 0.842676015

00:43:34.160 --> 00:43:35.912 No one really looked at the role of

NOTE Confidence: 0.842676015

00:43:35.912 --> 00:43:37.637 circulating tumor DNA in this setting, right?

NOTE Confidence: 0.842676015

00:43:37.637 --> 00:43:40.844 But in the phase three trial, that's I.

NOTE Confidence: 0.842676015

00:43:40.844 --> 00:43:42.972 I don't know, I presume won't be

NOTE Confidence: 0.842676015

00:43:42.972 --> 00:43:45.080 open for another 8 to 10 months.

NOTE Confidence: 0.842676015

00:43:45.080 --> 00:43:47.852 I hope they will also take that into account,

NOTE Confidence: 0.842676015

00:43:47.860 --> 00:43:49.309 and I think other trials are also

NOTE Confidence: 0.842676015

00:43:49.309 --> 00:43:50.758 trying to take that into account.

NOTE Confidence: 0.842676015

00:43:50.760 --> 00:43:53.142 And obviously 'cause that could impact

NOTE Confidence: 0.842676015

00:43:53.142 --> 00:43:55.100 our surveillance period as well.

NOTE Confidence: 0.842676015

00:43:55.100 --> 00:43:56.380 But I agree with you,

NOTE Confidence: 0.842676015

00:43:56.380 --> 00:43:57.066 you know,

NOTE Confidence: 0.842676015

00:43:57.066 --> 00:43:59.467 recurrent rectal cancer is one of the

NOTE Confidence: 0.842676015

00:43:59.467 --> 00:44:01.921 most challenging cancers because of the

NOTE Confidence: 0.842676015

00:44:01.921 --> 00:44:04.560 quality of life on patients because.

NOTE Confidence: 0.842676015

00:44:04.560 --> 00:44:08.445 Lost largely the involvement of the sacrum,

NOTE Confidence: 0.842676015

00:44:08.450 --> 00:44:10.050 when they have recurrent disease

NOTE Confidence: 0.842676015

00:44:10.050 --> 00:44:11.890 in the pain that means do.

NOTE Confidence: 0.842676015

00:44:11.890 --> 00:44:14.383 But I I it's very interesting when you talk

NOTE Confidence: 0.842676015

00:44:14.383 --> 00:44:16.946 to the national patient advocacy groups,

NOTE Confidence: 0.842676015

00:44:16.950 --> 00:44:17.350 you know,

NOTE Confidence: 0.842676015

00:44:17.350 --> 00:44:18.550 once you get a large number

NOTE Confidence: 0.842676015

00:44:18.550 --> 00:44:19.929 of them are younger patients,

NOTE Confidence: 0.842676015

00:44:19.930 --> 00:44:22.100 they are more than willing to take

NOTE Confidence: 0.842676015

00:44:22.100 --> 00:44:24.269 that risk to avoid the potential

NOTE Confidence: 0.842676015

00:44:24.269 --> 00:44:26.992 issues with bowel bowel issues to avoid

NOTE Confidence: 0.842676015

00:44:27.067 --> 00:44:29.167 even radiation therapy in the setting

NOTE Confidence: 0.842676015

00:44:29.167 --> 00:44:31.644 of the MSI high patient population

NOTE Confidence: 0.842676015

00:44:31.644 --> 00:44:34.329 because of toxicities as well.

NOTE Confidence: 0.842676015

00:44:34.330 --> 00:44:37.194 So they're really looking at quality of life.

NOTE Confidence: 0.842676015

00:44:37.200 --> 00:44:38.144 The majority of them,

NOTE Confidence: 0.842676015

00:44:38.144 --> 00:44:38.380 no,

NOTE Confidence: 0.842676015

00:44:38.380 --> 00:44:38.760 I think

NOTE Confidence: 0.828638490833333

00:44:38.770 --> 00:44:40.570 they're the ones that are low and you

NOTE Confidence: 0.828638490833333

00:44:40.570 --> 00:44:42.096 can avoid a stoma. They'll do it.

NOTE Confidence: 0.828638490833333

00:44:42.096 --> 00:44:43.580 I think the ones where the worry

NOTE Confidence: 0.828638490833333

00:44:43.630 --> 00:44:45.456 is is it's perhaps an LAR.

NOTE Confidence: 0.828638490833333

00:44:45.456 --> 00:44:46.816 And now you're dooming them

NOTE Confidence: 0.828638490833333

00:44:46.816 --> 00:44:48.668 to a recurrence and Eric will

NOTE Confidence: 0.828638490833333

00:44:48.668 --> 00:44:50.540 remember this in the late 90s.

NOTE Confidence: 0.828638490833333

00:44:50.540 --> 00:44:52.902 We were doing local excisions for T2T3,

NOTE Confidence: 0.828638490833333

00:44:52.902 --> 00:44:55.800 and then they were coming back with a APR.

NOTE Confidence: 0.828638490833333

00:44:55.800 --> 00:44:59.970 So I think that that perhaps is the part.

NOTE Confidence: 0.828638490833333

00:44:59.970 --> 00:45:02.469 That, I think would be a concern,

NOTE Confidence: 0.828638490833333

00:45:02.470 --> 00:45:04.252 and I think Brazilian data they

NOTE Confidence: 0.828638490833333

00:45:04.252 --> 00:45:05.890 follow their patients really closely,

NOTE Confidence: 0.828638490833333

00:45:05.890 --> 00:45:07.746 whereas we're not as as a

NOTE Confidence: 0.828638490833333

00:45:07.746 --> 00:45:09.018 coordinated system in America.

NOTE Confidence: 0.79383735875

00:45:10.560 --> 00:45:12.056 And and you have a very valid point,

NOTE Confidence: 0.79383735875

00:45:12.060 --> 00:45:15.900 but but patients are really motivated.

NOTE Confidence: 0.890071202

00:45:16.730 --> 00:45:18.538 Can I ask just a little question before

NOTE Confidence: 0.890071202

00:45:18.538 --> 00:45:20.387 you get to your big question needed?

NOTE Confidence: 0.890071202

00:45:20.390 --> 00:45:22.920 And my little question is.

NOTE Confidence: 0.890071202

00:45:22.920 --> 00:45:24.040 How do you you know?

NOTE Confidence: 0.890071202

00:45:24.040 --> 00:45:27.358 So I understand you follow people closely,

NOTE Confidence: 0.890071202

00:45:27.360 --> 00:45:30.978 but. How do you follow people closely?

NOTE Confidence: 0.890071202

00:45:30.980 --> 00:45:32.496 I mean you can't.

NOTE Confidence: 0.890071202

00:45:32.496 --> 00:45:34.391 You can't be biasing multiple

NOTE Confidence: 0.890071202

00:45:34.391 --> 00:45:36.177 little areas all the time,

NOTE Confidence: 0.890071202

00:45:36.180 --> 00:45:39.736 so you're following people closely with just,

NOTE Confidence: 0.890071202

00:45:39.740 --> 00:45:42.896 you know, some sort of scoping.

NOTE Confidence: 0.890071202

00:45:42.900 --> 00:45:44.646 You know, a low scoping procedure,

NOTE Confidence: 0.81343721625

00:45:44.940 --> 00:45:46.325 correct? We kind of followed

NOTE Confidence: 0.81343721625

00:45:46.325 --> 00:45:47.156 at our institution.

NOTE Confidence: 0.81343721625

00:45:47.160 --> 00:45:49.758 We kind of followed the memorial

NOTE Confidence: 0.81343721625

00:45:49.760 --> 00:45:53.030 data and have also done the

NOTE Confidence: 0.81343721625

00:45:53.030 --> 00:45:55.210 regular intervals with endoscopy.

NOTE Confidence: 0.81343721625

00:45:55.210 --> 00:45:58.470 Testing as well as diagnostic

NOTE Confidence: 0.81343721625

00:45:58.470 --> 00:46:00.426 imaging with MRI.

NOTE Confidence: 0.81343721625

00:46:00.430 --> 00:46:02.518 Yes Nita yeah no. I think

NOTE Confidence: 0.691858658

00:46:02.530 --> 00:46:03.310 Eric you hit the knee.

NOTE Confidence: 0.691858658

00:46:03.310 --> 00:46:04.760 I think who is examining

NOTE Confidence: 0.691858658

00:46:04.760 --> 00:46:06.210 and do they pay attention?

NOTE Confidence: 0.691858658

00:46:06.210 --> 00:46:07.420 I think that's the set.

NOTE Confidence: 0.691858658

00:46:07.420 --> 00:46:08.774 The second question perhaps is

NOTE Confidence: 0.691858658

00:46:08.774 --> 00:46:10.888 similar now that you know if you're

NOTE Confidence: 0.691858658

00:46:10.888 --> 00:46:12.930 looking at breast and standardization,

NOTE Confidence: 0.691858658

00:46:12.930 --> 00:46:15.520 I'd still sense that even though colorectal

NOTE Confidence: 0.691858658

00:46:15.520 --> 00:46:18.447 cancer is one of our most common cancers,

NOTE Confidence: 0.691858658

00:46:18.450 --> 00:46:21.378 there remains a gap in standardized

NOTE Confidence: 0.691858658

00:46:21.378 --> 00:46:22.830 testing and you just showed U.S.

NOTE Confidence: 0.691858658

00:46:22.830 --> 00:46:24.641 data of the 1% rule, right?

NOTE Confidence: 0.691858658

00:46:24.641 --> 00:46:25.646 The one person you know,

NOTE Confidence: 0.691858658

00:46:25.650 --> 00:46:28.386 the 3% hurt to the MSI.

NOTE Confidence: 0.691858658

00:46:28.390 --> 00:46:30.822 And how do we sort of work in

NOTE Confidence: 0.691858658

00:46:30.822 --> 00:46:32.538 national agencies in your role in?

NOTE Confidence: 0.691858658

00:46:32.540 --> 00:46:34.542 Starting to think about cancer and what

NOTE Confidence: 0.691858658

00:46:34.542 --> 00:46:36.599 should be the major things we test.

NOTE Confidence: 0.691858658

00:46:36.600 --> 00:46:39.880 I I still think it's a Wild West out there.

NOTE Confidence: 0.691858658

00:46:39.880 --> 00:46:41.553 If we ignore some of the top

NOTE Confidence: 0.691858658

00:46:41.553 --> 00:46:42.736 institutions you know when you

NOTE Confidence: 0.691858658

00:46:42.736 --> 00:46:44.185 get to the rest of the country

NOTE Confidence: 0.917322238

00:46:44.480 --> 00:46:46.260 I I would say that.

NOTE Confidence: 0.917322238

00:46:46.260 --> 00:46:48.290 From my experience thus far,

NOTE Confidence: 0.917322238

00:46:48.290 --> 00:46:49.970 I would say the majority of people

NOTE Confidence: 0.917322238

00:46:49.970 --> 00:46:51.698 do get tested for obviously rash.

NOTE Confidence: 0.917322238

00:46:51.700 --> 00:46:53.356 That has been the most common thing which,

NOTE Confidence: 0.917322238

00:46:53.360 --> 00:46:54.940 which obviously is extremely important.

NOTE Confidence: 0.917322238

00:46:54.940 --> 00:46:56.565 So then they can avoid

NOTE Confidence: 0.917322238

00:46:56.565 --> 00:46:57.924 anti EGFR therapy there.

NOTE Confidence: 0.917322238

00:46:57.924 --> 00:47:00.612 I fully agree with you though there

NOTE Confidence: 0.917322238

00:47:00.612 --> 00:47:02.542 are patients that still come to me

NOTE Confidence: 0.917322238

00:47:02.542 --> 00:47:04.498 that have never had the raft testing,

NOTE Confidence: 0.917322238

00:47:04.500 --> 00:47:06.420 which obviously is extremely important.

NOTE Confidence: 0.917322238

00:47:06.420 --> 00:47:09.282 They've never had MSI testing and

NOTE Confidence: 0.917322238

00:47:09.282 --> 00:47:11.396 you know I fully agree with you.

NOTE Confidence: 0.917322238

00:47:11.400 --> 00:47:13.966 I would just say that in every

NOTE Confidence: 0.917322238

00:47:13.966 --> 00:47:16.504 single lecture we give every single.

NOTE Confidence: 0.917322238

00:47:16.504 --> 00:47:19.318 Bit of publications that we can provide

NOTE Confidence: 0.917322238

00:47:19.318 --> 00:47:21.947 to individuals to educate others.

NOTE Confidence: 0.917322238

00:47:21.950 --> 00:47:24.838 We have to encourage that all patients need

NOTE Confidence: 0.917322238

00:47:24.838 --> 00:47:28.370 to be tested for molecular marker analysis.

NOTE Confidence: 0.917322238

00:47:28.370 --> 00:47:30.757 I mean, that is critical to their

NOTE Confidence: 0.917322238

00:47:30.757 --> 00:47:33.680 overall treatment and and you know

NOTE Confidence: 0.917322238

00:47:33.680 --> 00:47:37.100 it's it's so interesting when bearoff.

NOTE Confidence: 0.917322238

00:47:37.100 --> 00:47:39.650 So when Scott Kopetz originally

NOTE Confidence: 0.917322238

00:47:39.650 --> 00:47:41.530 talked about testing for BRAF,

NOTE Confidence: 0.917322238

00:47:41.530 --> 00:47:43.798 everybody thought he was crazy because

NOTE Confidence: 0.917322238

00:47:43.798 --> 00:47:47.140 it was such a rare patient population.

NOTE Confidence: 0.917322238

00:47:47.140 --> 00:47:49.100 And how we're going to get people to do that,

NOTE Confidence: 0.917322238

00:47:49.100 --> 00:47:51.218 but it's really as you know,

NOTE Confidence: 0.917322238

00:47:51.220 --> 00:47:52.910 it's a matter of education.

NOTE Confidence: 0.917322238

00:47:52.910 --> 00:47:54.258 And now it's it's.

NOTE Confidence: 0.917322238

00:47:54.258 --> 00:47:55.943 It's for the majority people.

NOTE Confidence: 0.917322238

00:47:55.950 --> 00:47:57.259 It is considered a standard of care.

NOTE Confidence: 0.917322238

00:47:57.260 --> 00:47:58.694 I would say a large number

NOTE Confidence: 0.917322238

00:47:58.694 --> 00:48:00.080 of people test for it now,

NOTE Confidence: 0.917322238

00:48:00.080 --> 00:48:01.940 but her two is still.

NOTE Confidence: 0.917322238

00:48:01.940 --> 00:48:03.172 It's still, you know,

NOTE Confidence: 0.917322238

00:48:03.172 --> 00:48:04.712 we're trying to get there,

NOTE Confidence: 0.917322238

00:48:04.720 --> 00:48:07.168 but her two is not commonly tested for,

NOTE Confidence: 0.813467806923077

00:48:07.560 --> 00:48:09.510 and Kathy does that affect treatment

NOTE Confidence: 0.813467806923077

00:48:09.510 --> 00:48:12.635 for stage one and stage two disease no?

NOTE Confidence: 0.813467806923077

00:48:12.635 --> 00:48:14.675 So, I mean, you're really talking

NOTE Confidence: 0.813467806923077

00:48:14.675 --> 00:48:15.719 about more advanced disease.

NOTE Confidence: 0.813467806923077

00:48:15.720 --> 00:48:16.788 We're testing is really.

86

NOTE Confidence: 0.804090052857143

00:48:17.250 --> 00:48:18.188 Critical, correct?

NOTE Confidence: 0.804090052857143

00:48:18.188 --> 00:48:21.002 Although obviously for MSI high we

NOTE Confidence: 0.804090052857143

00:48:21.002 --> 00:48:23.169 would encourage it in all stages.

NOTE Confidence: 0.804090052857143

00:48:23.170 --> 00:48:24.746 Yes, for largely metastatic

NOTE Confidence: 0.804090052857143

00:48:24.746 --> 00:48:27.110 disease 'cause we have not found

NOTE Confidence: 0.804090052857143

00:48:27.183 --> 00:48:29.215 benefit of these other targeted

NOTE Confidence: 0.804090052857143

00:48:29.215 --> 00:48:32.140 agents in early stage disease.

NOTE Confidence: 0.804090052857143

00:48:32.140 --> 00:48:34.400 We've tried.

NOTE Confidence: 0.804090052857143

00:48:34.400 --> 00:48:36.088 With anti EGFR therapy,

NOTE Confidence: 0.804090052857143

00:48:36.088 --> 00:48:38.198 we've tried with anti VEGF

NOTE Confidence: 0.804090052857143

00:48:38.198 --> 00:48:39.859 therapy and stage three,

NOTE Confidence: 0.804090052857143

00:48:39.860 --> 00:48:41.020 which was they were

NOTE Confidence: 0.804090052857143

00:48:41.020 --> 00:48:41.890 not successful studies.

NOTE Confidence: 0.9201518875

00:48:42.960 --> 00:48:46.744 OK, so I'm going to ask a question.

NOTE Confidence: 0.9201518875

00:48:46.750 --> 00:48:49.774 That you know, sort of a like big

NOTE Confidence: 0.9201518875

00:48:49.774 --> 00:48:52.668 question about the future or the present.

NOTE Confidence: 0.9201518875

00:48:52.670 --> 00:48:57.199 But if you had could do anything.

NOTE Confidence: 0.9201518875

00:48:57.200 --> 00:49:00.648 And the goal is to reduce colon cancer

NOTE Confidence: 0.9201518875

00:49:00.648 --> 00:49:03.258 deaths in the United States and beyond.

NOTE Confidence: 0.9201518875

00:49:03.260 --> 00:49:05.720 And you have two interventions

NOTE Confidence: 0.9201518875

00:49:05.720 --> 00:49:07.612 that you could use.

NOTE Confidence: 0.9201518875

00:49:07.612 --> 00:49:09.504 What would you do?

NOTE Confidence: 0.9201518875

00:49:09.510 --> 00:49:11.834 Two interventions or two interventions

NOTE Confidence: 0.9201518875

00:49:11.834 --> 00:49:13.596 or two two? You know?

NOTE Confidence: 0.9201518875

00:49:13.596 --> 00:49:15.714 What are the unmet needs so

NOTE Confidence: 0.9201518875

00:49:15.714 --> 00:49:17.977 the two biggest unmet needs

NOTE Confidence: 0.9201518875

00:49:17.977 --> 00:49:20.200 for colorectal cancer in 2022?

NOTE Confidence: 0.926941490833333

00:49:21.020 --> 00:49:22.945 I would say, well, the the number

NOTE Confidence: 0.926941490833333

00:49:22.945 --> 00:49:24.839 one needs still remains screening.

NOTE Confidence: 0.926941490833333

00:49:24.840 --> 00:49:27.258 I mean, in all fairness, we are still

NOTE Confidence: 0.926941490833333

00:49:27.258 --> 00:49:29.934 under screening in the United States.

NOTE Confidence: 0.926941490833333

00:49:29.940 --> 00:49:32.778 It's still I think it's like 78 percent is

NOTE Confidence: 0.926941490833333

00:49:32.778 --> 00:49:36.297 the best so so many people are being missed.

NOTE Confidence: 0.926941490833333

00:49:36.300 --> 00:49:37.940 And just because they don't

NOTE Confidence: 0.926941490833333

00:49:37.940 --> 00:49:41.351 want to be screened. Number 20.

NOTE Confidence: 0.926941490833333

00:49:41.351 --> 00:49:44.106 If I could do something

NOTE Confidence: 0.926941490833333

00:49:44.110 --> 00:49:45.550 and make it effective,

NOTE Confidence: 0.926941490833333

00:49:45.550 --> 00:49:49.298 I wish we could find some way to make IO

NOTE Confidence: 0.926941490833333

00:49:49.298 --> 00:49:51.970 therapy helpful in the majority of her MSI.

NOTE Confidence: 0.926941490833333

00:49:51.970 --> 00:49:54.470 Stable colorectal cancer patients.

NOTE Confidence: 0.926941490833333

00:49:54.470 --> 00:49:59.388 We appear to be at a standstill in regards

NOTE Confidence: 0.926941490833333

00:49:59.388 --> 00:50:02.070 to any potential combination thus far.

NOTE Confidence: 0.926941490833333

00:50:02.070 --> 00:50:04.410 It you know it has.

NOTE Confidence: 0.926941490833333

00:50:04.410 --> 00:50:06.426 It's worked well in other malignancies.

NOTE Confidence: 0.926941490833333

00:50:06.430 --> 00:50:10.930 Obviously, Upper GI, HTC Cholangio,

NOTE Confidence: 0.926941490833333

00:50:10.930 --> 00:50:13.050 and here we are still nowhere with it,

NOTE Confidence: 0.926941490833333

00:50:13.050 --> 00:50:13.391 really.

NOTE Confidence: 0.926941490833333

00:50:13.391 --> 00:50:14.414 In colorectal cancer,

NOTE Confidence: 0.926941490833333

00:50:14.414 --> 00:50:17.248 except the less than 5% with MSI HIGH.

NOTE Confidence: 0.926941490833333

00:50:17.248 --> 00:50:19.880 But screening I would rather prevent the

NOTE Confidence: 0.926941490833333

00:50:19.949 --> 00:50:22.885 colorectal cancer and not have to treat it.

NOTE Confidence: 0.926941490833333

00:50:22.890 --> 00:50:24.054 That would be my number one

NOTE Confidence: 0.926941490833333

00:50:24.054 --> 00:50:25.382 thing which I know sounds odd

NOTE Confidence: 0.926941490833333

00:50:25.382 --> 00:50:26.647 coming as a medical oncologist.

NOTE Confidence: 0.880749245294118

00:50:28.660 --> 00:50:31.156 Well look look, we all want to put

NOTE Confidence: 0.880749245294118

00:50:31.156 --> 00:50:32.883 ourselves out of work eventually

NOTE Confidence: 0.880749245294118

00:50:32.883 --> 00:50:35.298 and to what extent do health care

NOTE Confidence: 0.880749245294118

00:50:35.298 --> 00:50:37.028 disparities lay in tech excess

NOTE Confidence: 0.880749245294118

00:50:37.028 --> 00:50:38.950 debts in colorectal cancer?

NOTE Confidence: 0.85571975375

00:50:40.930 --> 00:50:43.150 So obviously this isn't.

NOTE Confidence: 0.85571975375

00:50:43.150 --> 00:50:46.226 This is an issue as you

NOTE Confidence: 0.85571975375

00:50:46.226 --> 00:50:48.366 know in our clinical trials.

NOTE Confidence: 0.85571975375

00:50:48.370 --> 00:50:49.888 As like many other clinical trials,

NOTE Confidence: 0.85571975375

00:50:49.890 --> 00:50:52.650 especially though in colorectal cancer,

NOTE Confidence: 0.85571975375

00:50:52.650 --> 00:50:55.401 the majority of patients that enroll in

NOTE Confidence: 0.85571975375

00:50:55.401 --> 00:50:58.485 clinical trials are not our average patients,

NOTE Confidence: 0.85571975375

00:50:58.485 --> 00:51:01.568 95% are of their Caucasian or white,

NOTE Confidence: 0.85571975375

00:51:01.568 --> 00:51:04.250 and the majority of patients do not

NOTE Confidence: 0.85571975375

00:51:04.250 --> 00:51:06.026 participate in clinical trials.

NOTE Confidence: 0.85571975375

00:51:06.030 --> 00:51:06.622 I wish I could.

NOTE Confidence: 0.85571975375

00:51:06.622 --> 00:51:07.950 So if the number if I could ask,

NOTE Confidence: 0.85571975375

00:51:07.950 --> 00:51:10.365 have a number three, I would get,

NOTE Confidence: 0.85571975375

00:51:10.370 --> 00:51:13.317 I would get more people to appreciate

NOTE Confidence: 0.85571975375

00:51:13.317 --> 00:51:15.809 the importance of clinical trials

NOTE Confidence: 0.85571975375

00:51:15.810 --> 00:51:17.240 and to help with enrollment,

NOTE Confidence: 0.85571975375

00:51:17.240 --> 00:51:19.256 and allow us to be able to provide.

NOTE Confidence: 0.85571975375

00:51:19.260 --> 00:51:21.372 The standard treatment arm in the

NOTE Confidence: 0.85571975375

00:51:21.372 --> 00:51:23.546 community you know and and that

NOTE Confidence: 0.85571975375

00:51:23.546 --> 00:51:25.296 way will help with enrollment,

NOTE Confidence: 0.85571975375

00:51:25.300 --> 00:51:27.100 so that would be my number three thing,

NOTE Confidence: 0.85571975375

00:51:27.100 --> 00:51:30.926 but in regards to diversity we are

NOTE Confidence: 0.85571975375

00:51:30.926 --> 00:51:33.636 lacking in clinical trials completely,

NOTE Confidence: 0.85571975375

00:51:33.640 --> 00:51:35.600 and a large number of the obviously

NOTE Confidence: 0.85571975375

00:51:35.600 --> 00:51:36.820 the datasets that exist.

NOTE Confidence: 0.85571975375

00:51:36.820 --> 00:51:38.910 So I love Andrea sirsak.

NOTE Confidence: 0.85571975375

00:51:38.910 --> 00:51:40.098 She's a friend of mine memorial,

NOTE Confidence: 0.85571975375

00:51:40.100 --> 00:51:42.473 but she just published a big publication

NOTE Confidence: 0.85571975375

00:51:42.473 --> 00:51:44.220 looking at mutations at Memorial.

NOTE Confidence: 0.85571975375

00:51:44.220 --> 00:51:46.474 It's one of the largest data sets,

NOTE Confidence: 0.85571975375

00:51:46.480 --> 00:51:49.570 but yet 95% of her patients.

NOTE Confidence: 0.85571975375

00:51:49.570 --> 00:51:50.300 Or white,

NOTE Confidence: 0.85571975375

00:51:50.300 --> 00:51:51.940 and so it's not representative

NOTE Confidence: 0.85571975375

00:51:51.940 --> 00:51:53.252 of the actual community.

NOTE Confidence: 0.85571975375

00:51:53.260 --> 00:51:54.055 Nothing against her.

NOTE Confidence: 0.85571975375

00:51:54.055 --> 00:51:55.380 It's the data she has,

NOTE Confidence: 0.85571975375

00:51:55.380 --> 00:51:57.125 but that's the patient population

NOTE Confidence: 0.85571975375

00:51:57.125 --> 00:51:58.870 that they have at Memorial.

NOTE Confidence: 0.6959972775

00:52:00.350 --> 00:52:02.086 The problem, so we have a kitten

NOTE Confidence: 0.6959972775

00:52:02.086 --> 00:52:03.420 question from Mary Kate Kelly,

NOTE Confidence: 0.6959972775

00:52:03.420 --> 00:52:04.496 and that question is,

NOTE Confidence: 0.6959972775

00:52:04.496 --> 00:52:06.537 there's a low fat diet or a

NOTE Confidence: 0.6959972775

00:52:06.537 --> 00:52:08.001 vegetarian diet help decrease

NOTE Confidence: 0.6959972775

00:52:08.001 --> 00:52:09.831 the chance of colorectal cancer.

NOTE Confidence: 0.913261877142857

00:52:10.630 --> 00:52:13.269 I would say definitely does not hurt.

NOTE Confidence: 0.913261877142857

00:52:13.270 --> 00:52:15.070 There's a lot of literature

NOTE Confidence: 0.913261877142857

00:52:15.070 --> 00:52:16.510 going back and forth.

NOTE Confidence: 0.913261877142857

00:52:16.510 --> 00:52:17.390 We're going in the diet.

NOTE Confidence: 0.913261877142857

00:52:17.390 --> 00:52:20.006 I think the majority of studies have shown.

NOTE Confidence: 0.913261877142857

00:52:20.010 --> 00:52:22.254 Obviously your tendency to

NOTE Confidence: 0.913261877142857

00:52:22.254 --> 00:52:26.640 obesity is is more of a concern.

NOTE Confidence: 0.913261877142857

00:52:26.640 --> 00:52:29.128 There was also a very very nice publication

NOTE Confidence: 0.913261877142857

00:52:29.128 --> 00:52:31.068 just recently from my colleague here,

NOTE Confidence: 0.913261877142857

00:52:31.070 --> 00:52:35.906 Martha Shrubsall and epidemiology looking at.

NOTE Confidence: 0.913261877142857

00:52:35.910 --> 00:52:39.278 Poly phenols, I believe.

NOTE Confidence: 0.913261877142857

00:52:39.280 --> 00:52:42.140 And the increased risk actually

NOTE Confidence: 0.913261877142857

00:52:42.140 --> 00:52:45.000 in the black patient population

NOTE Confidence: 0.913261877142857

00:52:45.000 --> 00:52:46.730 which was published just recently.

NOTE Confidence: 0.870439438571429

00:52:47.660 --> 00:52:51.587 And a related question just came in,

NOTE Confidence: 0.870439438571429

00:52:51.590 --> 00:52:53.240 which is in patients who

NOTE Confidence: 0.870439438571429

00:52:53.240 --> 00:52:54.560 have had colorectal cancer,

NOTE Confidence: 0.870439438571429

00:52:54.560 --> 00:52:56.820 and they say to you,

NOTE Confidence: 0.870439438571429

00:52:56.820 --> 00:52:58.828 what can I do to prevent a recurrence?

NOTE Confidence: 0.870439438571429

00:52:58.830 --> 00:53:01.956 Are there any data that would

NOTE Confidence: 0.870439438571429

00:53:01.956 --> 00:53:03.519 support lifestyle interventions

NOTE Confidence: 0.870439438571429

00:53:03.519 --> 00:53:05.724 such as exercise, diet,

NOTE Confidence: 0.870439438571429

00:53:05.724 --> 00:53:09.334 any any other sort of

NOTE Confidence: 0.870439438571429

00:53:09.334 --> 00:53:10.778 nutritional supplements,

NOTE Confidence: 0.870439438571429

00:53:10.780 --> 00:53:12.469 and finally, aspirin.

NOTE Confidence: 0.830426854285714

00:53:13.180 --> 00:53:17.415 Right, so there is data regarding aspirin

NOTE Confidence: 0.830426854285714

00:53:17.420 --> 00:53:20.374 that appears to be more beneficial in

NOTE Confidence: 0.830426854285714

00:53:20.374 --> 00:53:23.720 the PIK 3 CA mutation patient which

NOTE Confidence: 0.830426854285714

00:53:23.720 --> 00:53:26.302 is about 15 to 20% of our patients.

NOTE Confidence: 0.830426854285714

00:53:26.302 --> 00:53:28.978 Better baby aspirin seems to be fairly

NOTE Confidence: 0.830426854285714

00:53:28.978 --> 00:53:30.210 benign and potentially helpful.

NOTE Confidence: 0.830426854285714

00:53:30.210 --> 00:53:32.807 And then Jeff Meyer Heart has published

NOTE Confidence: 0.830426854285714

00:53:32.807 --> 00:53:35.740 before on the role of exercise as well.

NOTE Confidence: 0.830426854285714

00:53:35.740 --> 00:53:38.764 I would say all good healthy eating

NOTE Confidence: 0.830426854285714

00:53:38.764 --> 00:53:41.505 patterns and exercise obviously can't harm

NOTE Confidence: 0.830426854285714

00:53:41.505 --> 00:53:44.990 you and I would highly recommend them.

NOTE Confidence: 0.830426854285714

00:53:44.990 --> 00:53:48.130 And then there's been some.

NOTE Confidence: 0.830426854285714

00:53:48.130 --> 00:53:49.859 I would say those those the majority

NOTE Confidence: 0.830426854285714

00:53:49.859 --> 00:53:50.600 of the data.

NOTE Confidence: 0.664739854444445

00:53:52.860 --> 00:53:57.774 Alright, well, and and any data on vitamin D

NOTE Confidence: 0.91479172875

00:53:58.560 --> 00:54:02.102 that is an ongoing trial being led

NOTE Confidence: 0.91479172875

00:54:02.102 --> 00:54:04.591 by Kim Eing I think it is called

NOTE Confidence: 0.91479172875

00:54:04.591 --> 00:54:06.319 forgot the name of the trial.

NOTE Confidence: 0.91479172875

00:54:06.320 --> 00:54:08.568 I apologize, it is being run through the

NOTE Confidence: 0.91479172875

00:54:08.568 --> 00:54:10.679 alliance and so they are looking at that.

NOTE Confidence: 0.951155828

00:54:11.670 --> 00:54:15.200 Alright, well I think that I think everyone

NOTE Confidence: 0.951155828

00:54:15.200 --> 00:54:17.230 got a tremendous amount out of this.

NOTE Confidence: 0.951155828

00:54:17.230 --> 00:54:19.486 Thank you so much for joining us all,

NOTE Confidence: 0.951155828

00:54:19.490 --> 00:54:22.154 be it from a distance we we look forward

NOTE Confidence: 0.951155828

00:54:22.154 --> 00:54:25.210 to having you here in person at some time.

NOTE Confidence: 0.951155828

00:54:25.210 --> 00:54:28.122 And please please give our best to all

NOTE Confidence: 0.951155828

00:54:28.122 --> 00:54:30.646 our friends at Vanderbilt and we really

NOTE Confidence: 0.951155828

00:54:30.646 --> 00:54:32.312 enjoyed having you thank you so much.

NOTE Confidence: 0.7668139825

00:54:32.350 --> 00:54:34.326 Thank you so much. It's been my pleasure.

NOTE Confidence: 0.7668139825

00:54:34.330 --> 00:54:36.780 It's been great thanks. Have a great day.